KR102539450B1 - Method for manufacturing atopic dermatitis-improving cosmetic composition containing tarantula component - Google Patents
Method for manufacturing atopic dermatitis-improving cosmetic composition containing tarantula component Download PDFInfo
- Publication number
- KR102539450B1 KR102539450B1 KR1020230023688A KR20230023688A KR102539450B1 KR 102539450 B1 KR102539450 B1 KR 102539450B1 KR 1020230023688 A KR1020230023688 A KR 1020230023688A KR 20230023688 A KR20230023688 A KR 20230023688A KR 102539450 B1 KR102539450 B1 KR 102539450B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- extract
- mixed
- powder
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 239000002537 cosmetic Substances 0.000 title claims abstract description 51
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract description 12
- 201000008937 atopic dermatitis Diseases 0.000 title abstract description 12
- 241000239292 Theraphosidae Species 0.000 title abstract description 9
- 238000000034 method Methods 0.000 title description 11
- 239000000284 extract Substances 0.000 claims abstract description 214
- 239000000843 powder Substances 0.000 claims description 88
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 57
- 206010003645 Atopy Diseases 0.000 claims description 56
- 241000219793 Trifolium Species 0.000 claims description 55
- 238000002156 mixing Methods 0.000 claims description 43
- 241000736199 Paeonia Species 0.000 claims description 40
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 40
- 238000003809 water extraction Methods 0.000 claims description 37
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 36
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 210000001808 exosome Anatomy 0.000 claims description 32
- 238000004108 freeze drying Methods 0.000 claims description 29
- 239000007787 solid Substances 0.000 claims description 27
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 26
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 24
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 24
- 239000003921 oil Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 240000005085 Pancratium maritimum Species 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 23
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 22
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 20
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 20
- 229940045761 evening primrose extract Drugs 0.000 claims description 20
- 235000008524 evening primrose extract Nutrition 0.000 claims description 20
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 20
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 19
- 240000007594 Oryza sativa Species 0.000 claims description 19
- 235000007164 Oryza sativa Nutrition 0.000 claims description 19
- 235000009566 rice Nutrition 0.000 claims description 19
- 244000178870 Lavandula angustifolia Species 0.000 claims description 18
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 18
- 241000234479 Narcissus Species 0.000 claims description 17
- 239000001102 lavandula vera Substances 0.000 claims description 17
- 235000018219 lavender Nutrition 0.000 claims description 17
- 241000219925 Oenothera Species 0.000 claims description 16
- 235000004496 Oenothera biennis Nutrition 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 14
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 14
- 235000005152 nicotinamide Nutrition 0.000 claims description 14
- 239000011570 nicotinamide Substances 0.000 claims description 14
- 229960003966 nicotinamide Drugs 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 13
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 13
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 13
- 238000010298 pulverizing process Methods 0.000 claims description 13
- 229940032094 squalane Drugs 0.000 claims description 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 12
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 12
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims description 12
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 12
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 12
- 229960005305 adenosine Drugs 0.000 claims description 12
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 claims description 12
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 claims description 12
- 229920002674 hyaluronan Polymers 0.000 claims description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims description 12
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims description 12
- 229940087305 limonene Drugs 0.000 claims description 12
- 235000001510 limonene Nutrition 0.000 claims description 12
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims description 12
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 12
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 11
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 11
- 229930007744 linalool Natural products 0.000 claims description 11
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 11
- IQQRAVYLUAZUGX-UHFFFAOYSA-N 1-butyl-3-methylimidazolium Chemical compound CCCCN1C=C[N+](C)=C1 IQQRAVYLUAZUGX-UHFFFAOYSA-N 0.000 claims description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 244000025254 Cannabis sativa Species 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 244000297531 Lespedeza cuneata Species 0.000 claims description 7
- 239000011812 mixed powder Substances 0.000 claims description 7
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 6
- 241000862632 Soja Species 0.000 claims description 6
- 235000017803 cinnamon Nutrition 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 150000003949 imides Chemical class 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 241000205585 Aquilegia canadensis Species 0.000 claims 6
- 241001105098 Angelica keiskei Species 0.000 abstract 1
- 241001570521 Lonicera periclymenum Species 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 19
- 229920001817 Agar Polymers 0.000 description 16
- 241000219061 Rheum Species 0.000 description 16
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 16
- 235000010419 agar Nutrition 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 11
- 241000206672 Gelidium Species 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- 208000003251 Pruritus Diseases 0.000 description 8
- 230000007803 itching Effects 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 241001474374 Blennius Species 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000038548 Grammostola rosea Species 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229920001339 phlorotannin Polymers 0.000 description 3
- 229930182676 phlorotannins Natural products 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- FHYNTHBAMAEFJB-UHFFFAOYSA-N 8,8′-bieckol Chemical compound OC1=CC(O)=CC(OC=2C=3OC4=C(O)C(=C(O)C=C4OC=3C(O)=CC=2O)C=2C(=C3OC4=C(OC=5C=C(O)C=C(O)C=5)C(O)=CC(O)=C4OC3=CC=2O)O)=C1 FHYNTHBAMAEFJB-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241001676724 Codium fragile subsp. tomentosoides Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- DRZQFGYIIYNNEC-UHFFFAOYSA-N dieckol Chemical compound OC1=CC(O)=CC(OC=2C=3OC4=C(O)C=C(OC=5C(=CC(OC=6C=7OC8=C(O)C=C(O)C=C8OC=7C(O)=CC=6O)=CC=5O)O)C=C4OC=3C(O)=CC=2O)=C1 DRZQFGYIIYNNEC-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229940098330 gamma linoleic acid Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- SLWPBUMYPRVYIJ-UHFFFAOYSA-N phlorofucofuroeckol a Chemical compound OC1=CC(O)=CC(OC=2C=3OC4=C(C=5C6=C(O)C=C(O)C(OC=7C=C(O)C=C(O)C=7)=C6OC=5C=C4O)OC=3C(O)=CC=2O)=C1 SLWPBUMYPRVYIJ-UHFFFAOYSA-N 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000002708 spider venom Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 241001202987 Agaraceae Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 241000196222 Codium fragile Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101000831205 Danio rerio Dynein axonemal assembly factor 11 Proteins 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002036 Dieckol Polymers 0.000 description 1
- 102100024282 Dynein axonemal assembly factor 11 Human genes 0.000 description 1
- 229920002138 Eckol Polymers 0.000 description 1
- ARZMNZGBFNSOIR-UHFFFAOYSA-N Eckol Natural products OC1=CC(O)=C2OC3=CC(C)=CC(O)=C3OC2=C1OC1=CC(O)=CC(O)=C1 ARZMNZGBFNSOIR-UHFFFAOYSA-N 0.000 description 1
- 241000243681 Eisenia bicyclis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000206671 Gelidium amansii Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 101000831210 Homo sapiens Dynein axonemal assembly factor 11 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241000114343 Lonicera caprifolium Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 229920001372 Phlorofucofuroeckol A Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- PCZZRBGISTUIOA-UHFFFAOYSA-N eckol Chemical compound OC1=CC(O)=CC(OC=2C=3OC4=C(O)C=C(O)C=C4OC=3C(O)=CC=2O)=C1 PCZZRBGISTUIOA-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 238000010413 gardening Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 타란툴라 성분을 함유한 아토피 개선 화장료 조성물 제조 방법에 관한 것으로, 타란툴라로부터 얻어지는 펩타이드 성분을 포함하는 아토피 개선 화장료 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to a method for preparing a cosmetic composition for improving atopy containing a tarantula component, and relates to a cosmetic composition for improving atopy containing a peptide component obtained from tarantula and a method for manufacturing the same.
일반적으로, 아토피 피부는 종전 유아기에 주로 발생하여 태열이라고도 하였으며, 주로 각질층 내의 세라마이드(ceramides)의 함량이 감소 됨에 따라 발생하는 것으로서 각질층의 수분 유지기능이 떨어짐에 따라 피부가 건조되어 각질이 쉽게 일어나며 피부장벽(skin barrier) 기능이 저하됨에 따라 자극유발물질이 각질층 내로 침입하여 자극을 유발시키고, 정상피부에서는 침입하기 어려운 항원 단백질이 침입함에 따라 피부 알러지 등이 용이하게 발생하여 견디기 힘들 만큼의 소양증 증상을 나타낸다. 이러한 아토피 피부는 심하게 긁게 되면 습진, 켈로이드(keloid) 현상이 수반되고, 심한 각질화가 일어나게 된다. 특히 이러한 아토피 피부 질환은 성장하면서도 쉽게 치료되지 않아 성인인 경우 사회 생활이나 활동에 상당한 지장을 초래하게 되고, 급기야는 대인기피증 등의 심각한 사회 현상을 유발하기도 한다.In general, atopic skin occurs mainly in infancy and is also called fetal fever. It is mainly caused by a decrease in the content of ceramides in the stratum corneum. As the skin barrier function deteriorates, irritating substances penetrate into the stratum corneum and cause irritation. indicate When such atopic skin is severely scratched, eczema and keloid phenomena are accompanied, and severe keratinization occurs. In particular, these atopic skin diseases are not easily treated even as they grow, causing significant difficulties in social life or activities in adults, and eventually causing serious social phenomena such as social phobia.
이러한 아토피 피부에 대해서는 지금까지 크게 네 가지로 밝혀져 있는데, 첫째는 유전적 원인에 의한 것으로서 피부 보호기능을 담당하는 피부 보호막인 세포막의 인지질과 각질 세포 간의 결합물질인 세포 간 지질을 구성하는 필수지방산인 감마-리놀레인산(γ-linoleic acid:GLA)이 부족한 상태로 인해 피부 보호막을 단단하게 만들지 못하므로 피부 표면의 수분이 쉽게 소실되고, 외부 자극에 의해 쉽게 알러지가 발생한다는 것이다. 둘째로 환경적인 요인에 의한 것으로서 현대인의 주거환경이 주로 아파트 생활로 보편화되면서 생활환경이 매우 건조하고 밀폐된 상태로 변화됨에 따라 아토피 피부가 증가되고 있으며, 이로 인해 수분 보유력이 저하되고 피부 보호기능이 상실되어 적은 자극에 의해서도 민감하게 반응하여 알러지가 발생하는 것이다. 세째로 활성산소에 의한 것으로 활성산소에 의해 과산화지질이 생성하게 되고, 이것에 의해 아토피 피부가 발생한다는 것이다. 네째로 각종 유해 세균이나 바이러스, 곰팡이 등에 감염되어 발생하는 것으로 알려져 있고, 또 이러한 원인들이 복합적으로 관계하여 발생한다고 보고 있다.So far, four types of atopic skin have been identified. The first is due to genetic causes. Due to the lack of gamma-linoleic acid (GLA), the skin barrier cannot be hardened, so moisture on the skin surface is easily lost, and allergies easily occur due to external stimuli. Second, it is caused by environmental factors. As the residential environment of modern people is mainly apartment life, and the living environment changes to a very dry and closed state, atopic skin is increasing, which lowers the water retention capacity and improves the skin protection function. Allergy occurs due to a sensitive response even to small stimuli. Thirdly, it is caused by active oxygen, and lipid peroxide is generated by active oxygen, which causes atopic skin. Fourth, it is known to be caused by infection with various harmful bacteria, viruses, fungi, etc., and it is believed that these causes occur in a complex relationship.
이러한 아토피 피부를 개선하기 위하여 원칙적으로 피부를 청결히 하여 항원으로 작용할 수 있는 물질을 제거하고 피부 장벽 기능을 강화시켜 피부 건조화로 부터 피부를 지키기 위하여 부족한 세포간지질 성분인 세라마이드를 공급하여 각질층에 자극을 주지 않도록 물리적인 자극을 피하는 방법을 사용해 왔다. 그래서 아토피 피부를 개선하기 위하여 공지의 세라마이드, 리놀레인산 식물류 또는 광물성 오일 등의 성분들, 하이드로코티손(hydrocortisone)과 같은 스테로이드(steroid)제제 또는 특정의 식물 추출물을 일반적인 유화제품의 처방에 함유시키거나 인지질 성분인 레시틴(lecithin)을 이용하여 리포좀(liposome) 형태로 만들어 피부 각질층에 공급함으로써 보습효과 및 수분손실을 방지하기 위한 오일 막을 만들어주고 세균오염 등을 막아주기 위해 향균. 항염 기능의 성분을 강화한 피부 외용제 또는 화장료가 주로 사용되어 오고 있다.In order to improve such atopic skin, in principle, clean the skin to remove substances that can act as antigens, strengthen the skin barrier function, and supply ceramide, an intercellular lipid component that is insufficient to protect the skin from drying skin, to stimulate the stratum corneum. I have been using methods to avoid physical stimuli so as not to give them. Therefore, in order to improve atopic skin, ingredients such as known ceramides, linoleic acid plants or mineral oils, steroid agents such as hydrocortisone, or specific plant extracts are included in the formulation of general emulsifying products, or It is made into a liposome using lecithin, a phospholipid component, and supplied to the stratum corneum to create a moisturizing effect and an oil film to prevent water loss, and to prevent bacterial contamination. Skin external preparations or cosmetics with enhanced components of anti-inflammatory function have been mainly used.
그러나, 지금까지 알려진 상기와 같은 종래 방법들은, 아토피 피부의 예방과 치료에 어느 정도의 성과를 거두고 있으나 효과적인 측면이나 피부 안정성 측면에서 아직 많은 문제점을 지니고 있다. 예컨대 아토피 피부용 외용제에 사용되는 스테로이드제의 사용은 표피의 성장억제나 부작용 등의 역효과를 유발할 수 있다고 보고되고 있으며, 우레아 프록사이드 등은 피부의 자극성과 또 다른 접촉성 피부염의 우려가 있고, 또 항히스타민제와 같은 항생물질은 내균성의 발생과 광 과민 작용의 가능성이 있다고 알려져 있다. 또한 일부 약제 추출물을 이용한 화장료의 경우 알레르기 과민 반응을 일으키는 경우가 있어 그 사용에 제한이 있을 수밖에 벗는 문제가 있는 것이어서 범용적으로 안전하게 사용하기에는 무리가 있다.However, the conventional methods as described above, which have been known so far, have achieved some success in preventing and treating atopic skin, but still have many problems in terms of effectiveness or skin stability. For example, it has been reported that the use of steroids used in external preparations for atopic skin can cause adverse effects such as epidermal growth inhibition or side effects, and urea proxide has concerns about skin irritation and other contact dermatitis, and antihistamines. It is known that antibiotics such as antibiotics have the possibility of developing bacterial resistance and photosensitization. In addition, in the case of cosmetics using some drug extracts, there is a problem in that there is a problem in that there is a problem in that there is a limitation in use because there is a case of allergic hypersensitivity reaction.
한편, 칠레 로즈 타란툴라(Chilian Rose Tarantula(학명: Grammostula spatulata)) 거미에 의해 분비되는 독에서 추출한 GsMTx4 펩타이드는 34개의 아미노산(분자량:약 4kDa)을 갖고, 다른 유사한 펩타이드 독소와는 약 50% 정도의 상동성을 갖는 것으로 알려져 있으며(Oswald RE et al., J Biol Chem. 277(37):34443-50, 2002), 그라모스톨라 스파툴라타(Grammostola spatulata) 거미독에서 GsMTx4 펩타이드 이외에 SAC에 대해 억제 활성을 갖는 기타 펩타이드(Sachs, F., unpublished observations) 및 GsMTx-1(미국 특허 제 5756663 호)이 분리되었다(Thomas M. Suchyna, Janice H. Johnson, Katherine Hamer, Joseph F. Leykam, Douglas A. Gage, Henry F. Clemo, Clive M. Baumgarten, and Frederick Sachs, The Journal of General Phyiology, Volume 115, Number 5, 583-598, May 1, 2000).On the other hand, the GsMTx4 peptide extracted from the poison secreted by the Chilean Rose Tarantula (scientific name: Grammostula spatulata) spider has 34 amino acids (molecular weight: about 4 kDa) and is about 50% less effective than other similar peptide toxins. It is known to have homology (Oswald RE et al., J Biol Chem. 277(37):34443-50, 2002), and inhibits SAC in addition to the GsMTx4 peptide in Grammostola spatulata spider venom. Other peptides with activity (Sachs, F., unpublished observations) and GsMTx-1 (US Pat. No. 5756663) have been isolated (Thomas M. Suchyna, Janice H. Johnson, Katherine Hamer, Joseph F. Leykam, Douglas A. Gage, Henry F. Clemo, Clive M. Baumgarten, and Frederick Sachs, The Journal of General Phyiology, Volume 115, Number 5, 583-598, May 1, 2000).
또한, 대한민국등록특허 제10-0761792호에서는 칠레 로즈 타란툴라 거미독에서 추출한 GsMTx4 펩타이드가 통증유발물질로 자극에 대해 과민한 반응을 보이는 모델에서 기계적 자극에 의해 활성화되는 통각신경세포의 MSC의 활성을 억제함으로써 진통제로서 기능을 한다는 것이 밝혀졌다. 하지만 아토피를 개선하기 위한 조성물로의 적용은 미미한 실정으로 연구가 더욱 필요한 실정이다.In addition, Korean Patent Registration No. 10-0761792 discloses that the GsMTx4 peptide extracted from Chilean rose tarantula spider venom is a pain-inducing substance and suppresses the MSC activity of nociceptive neurons activated by mechanical stimulation in a model showing hypersensitivity to stimulation. It has been found to function as an analgesic. However, application as a composition for improving atopy is insignificant, and more research is needed.
본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로서, 본 발명의 목적은 타란툴라 성분과 신선초 추출물을 배합한 아토피 개선에 효과적인 화장료 조성물을 제공하는 것이다.The present invention has been made to solve the above problems, and an object of the present invention is to provide a cosmetic composition effective for improving atopy by combining a tarantula component and an extract of Sinensis.
본 발명의 과제는 이상에서 언급한 과제들로 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.The object of the present invention is not limited to the tasks mentioned above, and other tasks not mentioned will be clearly understood by those skilled in the art from the following description.
상기 목적을 달성하기 위하여 본 발명은In order to achieve the above object, the present invention
타란툴라 성분 및 신선초 추출물을 함유한 아토피 개선용 화장료 조성물을 제공한다.Provided is a cosmetic composition for improving atopy containing a tarantula component and an extract of Sintacola.
또한, 상기 아토피 개선용 화장료 조성물은,In addition, the cosmetic composition for improving atopy,
그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 1-5 중량부, 신선초잎 추출물 0.3-3 중량부, 싸리나무잎 추출물 0.3-3 중량부, 인동덩굴잎 추출물 0.3-3 중량부, 싸리나무꽃 추출물 0.3-3 중량부, 작약꽃 추출물 0.3-3 중량부, 달맞이꽃 추출물 0.3-3 중량부, 바다수선화 오일 0.3-3 중량부, 라벤더 오일 0.3-3 중량부, 소자 유래 엑소좀 0.3-3 중량부, 나이아신아마이드 0.5-4 중량부, 아르기닌 0.3-3 중량부, 아데노신 0.3-3 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.3-3 중량부, 트라이에틸헥사노인 0.3-3 중량부, 스쿠알란 3-7 중량부, 부틸렌글라이콜 2-6 중량부, 프로필렌글라이콜 0.05-0.2 중량부, 폴리글리세릴-6스테아레이트 0.05-0.2 중량부, 스테아릴알코올 0.05-0.2 중량부, 이소퀘르시트린 0.05-0.2 중량부, 하이알루로닉애씨드 0.5-4 중량부, 소듐하이알루로네이트 0.05-0.2 중량부, 리모넨 0.3-0.7 중량부, 리날룰 0.3-3 중량부 및 브로콜리수 67-71 중량부를 포함하는 것을 특징으로 한다.1-5 parts by weight of Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, 0.3-3 parts by weight of fresh grass leaf extract, 0.3-3 parts by weight of clover clover leaf extract, 0.3-3 parts by weight of honeysuckle leaf extract 3 parts by weight, clover flower extract 0.3-3 parts by weight, peony flower extract 0.3-3 parts by weight, evening primrose extract 0.3-3 parts by weight, sea daffodil oil 0.3-3 parts by weight, lavender oil 0.3-3 parts by weight, derived from Soja Exosome 0.3-3 parts by weight, niacinamide 0.5-4 parts by weight, arginine 0.3-3 parts by weight, adenosine 0.3-3 parts by weight, diethylaminohydroxybenzoylhexylbenzoate 0.3-3 parts by weight, triethylhexanoin 0.3 -3 parts by weight, squalane 3-7 parts by weight, butylene glycol 2-6 parts by weight, propylene glycol 0.05-0.2 parts by weight, polyglyceryl-6 stearate 0.05-0.2 parts by weight, stearyl alcohol 0.05- 0.2 parts by weight, isoquercitrin 0.05-0.2 parts by weight, hyaluronic acid 0.5-4 parts by weight, sodium hyaluronate 0.05-0.2 parts by weight, limonene 0.3-0.7 parts by weight, linalool 0.3-3 parts by weight, and It is characterized in that it comprises 67-71 parts by weight of broccoli water.
또한, 상기 아토피 개선용 화장료 조성물은,In addition, the cosmetic composition for improving atopy,
그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 2-4 중량부, 신선초잎 추출물 0.5-1.5 중량부, 싸리나무잎 추출물 0.5-1.5 중량부, 인동덩굴잎 추출물 0.5-1.5 중량부, 싸리나무꽃 추출물 0.5-1.5 중량부, 작약꽃 추출물 0.5-1.5 중량부, 달맞이꽃 추출물 0.5-1.5 중량부, 바다수선화 오일 0.5-1.5 중량부, 라벤더 오일 0.5-1.5 중량부, 소자 유래 엑소좀 0.5-1.5 중량부, 나이아신아마이드 1-3 중량부, 아르기닌 0.5-1.5 중량부, 아데노신 0.5-1.5 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.5-1.5 중량부, 트라이에틸헥사노인 0.5-1.5 중량부, 스쿠알란 4-6 중량부, 부틸렌글라이콜 3-5 중량부, 프로필렌글라이콜 0.08-0.12 중량부, 폴리글리세릴-6스테아레이트 0.08-0.12 중량부, 스테아릴알코올 0.08-0.12 중량부, 이소퀘르시트린 0.08-0.12 중량부, 하이알루로닉애씨드 1-3 중량부, 소듐하이알루로네이트 0.08-0.12 중량부, 리모넨 0.4-0.6 중량부, 리날룰 0.5-1.5 중량부 및 브로콜리수 68-70 중량부를 포함하는 것을 특징으로 한다.2-4 parts by weight of Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, 0.5-1.5 parts by weight of fresh grass leaf extract, 0.5-1.5 parts by weight of clover leaf extract, 0.5-1.5 parts by weight of honeysuckle leaf extract 1.5 parts by weight, clover flower extract 0.5-1.5 parts by weight, peony flower extract 0.5-1.5 parts by weight, evening primrose extract 0.5-1.5 parts by weight, sea daffodil oil 0.5-1.5 parts by weight, lavender oil 0.5-1.5 parts by weight, Soja Exosome 0.5-1.5 parts by weight, niacinamide 1-3 parts by weight, arginine 0.5-1.5 parts by weight, adenosine 0.5-1.5 parts by weight, diethylaminohydroxybenzoylhexylbenzoate 0.5-1.5 parts by weight, triethylhexanoin 0.5 parts by weight -1.5 parts by weight, squalane 4-6 parts by weight, butylene glycol 3-5 parts by weight, propylene glycol 0.08-0.12 parts by weight, polyglyceryl-6 stearate 0.08-0.12 parts by weight, stearyl alcohol 0.08- 0.12 parts by weight, isoquercitrin 0.08-0.12 parts by weight, hyaluronic acid 1-3 parts by weight, sodium hyaluronate 0.08-0.12 parts by weight, limonene 0.4-0.6 parts by weight, linalool 0.5-1.5 parts by weight and It is characterized in that it comprises 68-70 parts by weight of broccoli water.
또한, 본 발명은In addition, the present invention
신선초잎, 싸리나무잎 및 인동덩굴잎을 세척하고 동결건조한 후 분쇄하여 신선초잎분말, 싸리나무잎분말 및 인동덩굴잎분말을 준비하는 단계; 준비된 신선초잎분말, 싸리나무잎분말 및 인동덩굴잎분말을 1:1:1의 중량비율로 혼합한 혼합분말을 에탄올 및 헥산을 1:1의 부피비로 혼합한 혼합 용매와 1:9의 중량비율로 혼합하고, 28-32℃의 온도에서 22-26시간 동안 추출하여 추출액을 제조하는 단계; 및 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 50℃에서 감압농축 및 동결건조하는 단계;를 포함하는 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물을 제조하는 단계;Preparing fresh herb leaf powder, clover clover leaf powder, and honeysuckle leaf powder by washing, freeze-drying, and pulverizing fresh herb leaves, clover clover leaf and honeysuckle leaf; Prepared fresh herb leaf powder, clover leaf powder and honeysuckle leaf powder were mixed in a weight ratio of 1: 1: 1, and a mixed solvent in which ethanol and hexane were mixed in a volume ratio of 1: 1 and a weight ratio of 1: 9 preparing an extract by mixing and extracting at a temperature of 28-32 ° C for 22-26 hours; and filtering the extract with a filter paper, concentrating the filtered filtrate under reduced pressure and freeze-drying the filtrate at minus 50 ° C.
싸리나무꽃, 작약꽃 및 달맞이꽃을 세척하고 동결건조한 후 분쇄하여 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 제조하는 단계; 제조된 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 1:1:1의 중량비율로 혼합한 혼합분말 20 g을 물 200 ml와 혼합하고, 교반하면서 80℃의 온도에서 8시간 동안 1차 열수추출을 수행하는 단계; 1차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 1차 혼합추출물을 제조하는 단계; 1차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 교반하면서 120℃의 온도에서 12시간 동안 2차 열수추출을 수행하는 단계; 2차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 2차 혼합추출물을 제조하는 단계; 2차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 여기에 [BMIm][TFSI](1-Butyl-3-methylimidazoliumbis trifluoromethylsulfonyl)imide)를 1-2 g 첨가한 후 교반하면서 100℃의 온도에서 8시간 동안 3차 열수추출을 수행하는 단계; 3차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 3차 혼합추출물을 제조하는 단계; 및 상기 1차 혼합추출물, 2차 혼합추출물 및 3차 혼합추출물을 혼합하는 단계;를 포함하는 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물을 제조하는 단계;Preparing clover flower powder, peony flower powder, and evening primrose powder by washing, freeze-drying, and pulverizing clover flower, peony flower, and evening primrose; 20 g of the prepared mixed powder of clover flower powder, peony flower powder, and evening primrose powder mixed in a weight ratio of 1:1:1 was mixed with 200 ml of water, followed by primary hot water at 80°C for 8 hours while stirring. performing an extraction; After the first hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a first mixed extract; After the first hot water extraction, the remaining solids were filtered with filter paper, and the remaining solids were mixed with water so that the mixing ratio of the solids and water was 0.1 g/ml, and the second hot water extraction was performed at a temperature of 120 ° C for 12 hours while stirring. doing; After secondary hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a secondary mixed extract; After the second hot water extraction, filter with filter paper, and mix the remaining solids with water again so that the mixing ratio of solids and water is 0.1 g/ml, and [BMIm][TFSI](1-Butyl-3-methylimidazolium After adding 1-2 g of trifluoromethylsulfonyl)imide), performing a third hot water extraction at a temperature of 100 ° C. for 8 hours while stirring; After tertiary hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a tertiary mixed extract; And mixing the first mixed extract, the second mixed extract and the tertiary mixed extract; preparing a bush clover flower extract, a peony flower extract and an evening primrose extract containing;
바다수선화 및 라벤더를 분쇄하여 바다수선화분말 및 라벤더분말을 준비하는 단계; 상기 바다수선화분말 및 라벤더분말을 1:1의 중량비율로 혼합한 혼합분말 및 헥산을 혼합하고, 33-37℃의 온도에서 2-4일 동안 교반하여 추출물을 제조하는 단계; 및 상기 추출물을 여과하고 감압농축한 후 원심분리하여 이물질을 제거한 후, 감압증류하는 단계;를 포함하는 바다수선화 오일 및 라벤더 오일을 제조하는 단계;Preparing sea daffodil powder and lavender powder by crushing sea daffodil and lavender; preparing an extract by mixing a mixture of daffodil powder and lavender powder in a weight ratio of 1:1 with hexane and stirring at a temperature of 33-37 ° C. for 2-4 days; Preparing sea daffodil oil and lavender oil comprising; filtering and concentrating the extract under reduced pressure, centrifuging to remove foreign substances, and distilling under reduced pressure;
소자를 세척하여 28-32℃의 온도에서 290-310 MPa의 압력으로 1-5분 동안 전처리하는 단계; 전처리된 소자를 착즙하여 소자 착즙액을 제조하는 단계; 상기 소자 착즙액을 원심분리하여 엑소좀을 포함하는 상층액을 수득하는 단계; 상기 엑소좀을 포함하는 상층액을 동결건조하여 동결건조물을 제조하는 단계; 상기 동결건조물에 폴리에틸렌글리콜/덱스트란을 사용하여 수성 2상계를 형성하는 단계; 및 상기 수성 2상계 내 엑소좀이 농축된 하층액을 수득하는 단계;를 포함하는 소자 유래 엑소좀을 제조하는 단계;washing the device and pre-treating it at a temperature of 28-32° C. and a pressure of 290-310 MPa for 1-5 minutes; Preparing a device juice by extracting the pretreated device; Obtaining a supernatant containing exosomes by centrifuging the juice from the cow; preparing a lyophilisate by freeze-drying the supernatant containing the exosomes; forming an aqueous two-phase system using polyethylene glycol/dextran in the lyophilisate; and obtaining an exosome-enriched lower layer in the aqueous two-phase system; preparing a device-derived exosome comprising;
그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 1-5 중량부, 상기에서 제조된 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물 1-5 중량부, 상기에서 제조된 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물 1-5 중량부, 상기에서 제조된 소자 유래 엑소좀 0.3-3 중량부, 나이아신아마이드 0.5-4 중량부, 아르기닌 0.3-3 중량부, 아데노신 0.3-3 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.3-3 중량부, 트라이에틸헥사노인 0.3-3 중량부, 스테아릴알코올 0.05-0.2 중량부, 이소퀘르시트린 0.05-0.2 중량부, 하이알루로닉애씨드 0.5-4 중량부, 소듐하이알루로네이트 0.05-0.2 중량부, 리모넨 0.3-0.7 중량부, 리날룰 0.3-3 중량부 및 브로콜리수 47-51 중량부를 혼합하고, 68-72℃의 온도에서 28-32분 동안 교반하여 제1 혼합조성물을 제조하는 단계;1-5 parts by weight of Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, 1-5 parts by weight of the above-prepared cinnamon leaf extract, clover clover leaf extract and honeysuckle leaf extract, 1-5 parts by weight of Hsagi flower extract, peony flower extract and evening primrose extract prepared above, 0.3-3 parts by weight of the device-derived exosome prepared above, 0.5-4 parts by weight of niacinamide, 0.3-3 parts by weight of arginine, 0.3 parts by weight of adenosine -3 parts by weight, diethylaminohydroxybenzoylhexylbenzoate 0.3-3 parts by weight, triethylhexanoin 0.3-3 parts by weight, stearyl alcohol 0.05-0.2 parts by weight, isoquercitrin 0.05-0.2 parts by weight, hyaluronic acid 0.5-4 parts by weight of rhonic acid, 0.05-0.2 parts by weight of sodium hyaluronate, 0.3-0.7 parts by weight of limonene, 0.3-3 parts by weight of linalool and 47-51 parts by weight of broccoli water were mixed, and Stirring for 28-32 minutes at a temperature to prepare a first mixed composition;
상기에서 제조된 바다수선화 오일 및 라벤더 오일 0.5-4 중량부, 스쿠알란 3-7 중량부, 부틸렌글라이콜 2-6 중량부, 프로필렌글라이콜 0.05-0.2 중량부, 폴리글리세릴-6스테아레이트 0.05-0.2 중량부 및 브로콜리수 18-22 중량부를 혼합하고, 38-42℃의 온도에서 58-62분 동안 교반하여 제2 혼합조성물을 제조하는 단계; 및0.5-4 parts by weight of daffodil oil and lavender oil prepared above, 3-7 parts by weight of squalane, 2-6 parts by weight of butylene glycol, 0.05-0.2 parts by weight of propylene glycol, polyglyceryl-6 stearate Preparing a second mixed composition by mixing 0.05-0.2 parts by weight and 18-22 parts by weight of broccoli water and stirring at a temperature of 38-42 ° C. for 58-62 minutes; and
상기 제1 혼합조성물 및 상기 제2 혼합조성물을 혼합하고, 48-52℃의 온도에서 18-22분 동안 교반하는 단계;를 포함하는 아토피 개선용 화장료 조성물의 제조방법을 제공한다.It provides a method for producing a cosmetic composition for improving atopic dermatitis, comprising: mixing the first mixed composition and the second mixed composition and stirring for 18-22 minutes at a temperature of 48-52 ° C.
또한, 상기 제1 혼합조성물은 미강 발효추출물을 0.3-3 중량부 포함하는 것을 특징으로 한다.In addition, the first mixed composition is characterized in that it comprises 0.3-3 parts by weight of rice bran fermented extract.
본 발명에 따른 아토피 개선용 화장료 조성물은 타란툴라 성분과 신선초 추출물을 배합하여 아토피 개선에 효과적이다.The cosmetic composition for improving atopy according to the present invention is effective in improving atopy by combining a tarantula component and an extract of cinnamon plant.
도 1은 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법을 순서도로 나타낸 것이다.1 is a flow chart showing a method for producing a cosmetic composition for improving atopy according to the present invention.
이하에서는 첨부된 도면을 참조하여 다양한 실시예를 보다 상세하게 설명한다. 본 명세서에 기재된 실시예는 다양하게 변형될 수 있다. 특정한 실시예가 도면에서 묘사되고 상세한 설명에서 자세하게 설명될 수 있다. 그러나 첨부된 도면에 개시된 특정한 실시 예는 다양한 실시예를 쉽게 이해하도록 하기 위한 것일 뿐이다. 따라서 첨부된 도면에 개시된 특정 실시예에 의해 기술적 사상이 제한되는 것은 아니며, 발명의 사상 및 기술 범위에 포함되는 모든 균등물 또는 대체물을 포함하는 것으로 이해되어야 한다.Hereinafter, various embodiments will be described in more detail with reference to the accompanying drawings. The embodiments described in this specification may be modified in various ways. Certain embodiments may be depicted in the drawings and described in detail in the detailed description. However, specific embodiments disclosed in the accompanying drawings are only intended to facilitate understanding of various embodiments. Therefore, the technical idea is not limited by the specific embodiments disclosed in the accompanying drawings, and it should be understood to include all equivalents or substitutes included in the spirit and technical scope of the invention.
1차, 2차, 제1, 제2 등과 같이 서수를 포함하는 용어는 다양한 구성요소들을 설명하는데 사용될 수 있지만, 이러한 구성요소들은 상술한 용어에 의해 한정되지는 않는다. 상술한 용어는 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 사용된다.Terms including ordinal numbers such as primary, secondary, first, and second may be used to describe various elements, but these elements are not limited by the above-mentioned terms. The terminology described above is only used for the purpose of distinguishing one component from another.
본 명세서에서, '포함한다' 또는 '가지다' 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다. 어떤 구성요소가 다른 구성요소에 '연결되어' 있다거나 '접속되어' 있다고 언급된 때에는, 그 다른 구성요소에 직접적으로 연결되어 있거나 또는 접속되어 있을 수도 있지만, 중간에 다른 구성요소가 존재할 수도 있다고 이해되어야 할 것이다. 반면에, 어떤 구성요소가 다른 구성요소에 '직접 연결되어' 있다거나 '직접 접속되어' 있다고 언급된 때에는, 중간에 다른 구성요소가 존재하지 않는 것으로 이해되어야 할 것이다.In this specification, terms such as 'comprise' or 'having' are intended to designate that there is a feature, number, step, operation, component, part, or combination thereof described in the specification, but one or more other features It should be understood that the presence or addition of numbers, steps, operations, components, parts, or combinations thereof is not precluded. It is understood that when a component is referred to as being 'connected' or 'connected' to another component, it may be directly connected or connected to the other component, but other components may exist in the middle. It should be. On the other hand, when a component is referred to as being 'directly connected' or 'directly connected' to another component, it should be understood that no other component exists in the middle.
그 밖에도, 본 발명을 설명함에 있어서, 관련된 공지 기능 혹은 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우, 그에 대한 상세한 설명은 축약하거나 생략한다.In addition, in describing the present invention, if it is determined that a detailed description of a related known function or configuration may unnecessarily obscure the subject matter of the present invention, the detailed description thereof will be abbreviated or omitted.
본 발명은the present invention
타란툴라 성분 및 신선초 추출물을 함유한 아토피 개선용 화장료 조성물을 제공한다.Provided is a cosmetic composition for improving atopy containing a tarantula component and an extract of Sintacola.
이하, 본 발명에 따른 아토피 개선용 화장료 조성물에 대하여 상세히 설명한다.Hereinafter, the cosmetic composition for improving atopy according to the present invention will be described in detail.
본 발명에 따른 아토피 개선용 화장료 조성물은 타란툴라 성분과 신선초 추출물을 배합하여 아토피 개선에 효과적이다.The cosmetic composition for improving atopy according to the present invention is effective in improving atopy by combining a tarantula component and an extract of cinnamon plant.
상기 아토피 개선용 화장료 조성물은 그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 1-5 중량부, 신선초잎 추출물 0.3-3 중량부, 싸리나무잎 추출물 0.3-3 중량부, 인동덩굴잎 추출물 0.3-3 중량부, 싸리나무꽃 추출물 0.3-3 중량부, 작약꽃 추출물 0.3-3 중량부, 달맞이꽃 추출물 0.3-3 중량부, 바다수선화 오일 0.3-3 중량부, 라벤더 오일 0.3-3 중량부, 소자 유래 엑소좀 0.3-3 중량부, 나이아신아마이드 0.5-4 중량부, 아르기닌 0.3-3 중량부, 아데노신 0.3-3 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.3-3 중량부, 트라이에틸헥사노인 0.3-3 중량부, 스쿠알란 3-7 중량부, 부틸렌글라이콜 2-6 중량부, 프로필렌글라이콜 0.05-0.2 중량부, 폴리글리세릴-6스테아레이트 0.05-0.2 중량부, 스테아릴알코올 0.05-0.2 중량부, 이소퀘르시트린 0.05-0.2 중량부, 하이알루로닉애씨드 0.5-4 중량부, 소듐하이알루로네이트 0.05-0.2 중량부, 리모넨 0.3-0.7 중량부, 리날룰 0.3-3 중량부 및 브로콜리수 67-71 중량부를 포함하는 것이 바람직하고, 그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 2-4 중량부, 신선초잎 추출물 0.5-1.5 중량부, 싸리나무잎 추출물 0.5-1.5 중량부, 인동덩굴잎 추출물 0.5-1.5 중량부, 싸리나무꽃 추출물 0.5-1.5 중량부, 작약꽃 추출물 0.5-1.5 중량부, 달맞이꽃 추출물 0.5-1.5 중량부, 바다수선화 오일 0.5-1.5 중량부, 라벤더 오일 0.5-1.5 중량부, 소자 유래 엑소좀 0.5-1.5 중량부, 나이아신아마이드 1-3 중량부, 아르기닌 0.5-1.5 중량부, 아데노신 0.5-1.5 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.5-1.5 중량부, 트라이에틸헥사노인 0.5-1.5 중량부, 스쿠알란 4-6 중량부, 부틸렌글라이콜 3-5 중량부, 프로필렌글라이콜 0.08-0.12 중량부, 폴리글리세릴-6스테아레이트 0.08-0.12 중량부, 스테아릴알코올 0.08-0.12 중량부, 이소퀘르시트린 0.08-0.12 중량부, 하이알루로닉애씨드 1-3 중량부, 소듐하이알루로네이트 0.08-0.12 중량부, 리모넨 0.4-0.6 중량부, 리날룰 0.5-1.5 중량부 및 브로콜리수 68-70 중량부를 포함하는 것이 더욱 바람직하다.The cosmetic composition for improving atopy includes 1-5 parts by weight of Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, 0.3-3 parts by weight of fresh grass leaf extract, and 0.3-3 parts by weight of clover leaf extract. , honeysuckle leaf extract 0.3-3 parts by weight, clover flower extract 0.3-3 parts by weight, peony flower extract 0.3-3 parts by weight, evening primrose extract 0.3-3 parts by weight, sea daffodil oil 0.3-3 parts by weight, lavender oil 0.3 parts by weight -3 parts by weight, soma-derived exosome 0.3-3 parts by weight, niacinamide 0.5-4 parts by weight, arginine 0.3-3 parts by weight, adenosine 0.3-3 parts by weight, diethylaminohydroxybenzoylhexylbenzoate 0.3-3 parts by weight 0.3-3 parts by weight of triethylhexanoin, 3-7 parts by weight of squalane, 2-6 parts by weight of butylene glycol, 0.05-0.2 parts by weight of propylene glycol, 0.05-0.2 parts by weight of polyglyceryl-6stearate stearyl alcohol 0.05-0.2 parts by weight, isoquercitrin 0.05-0.2 parts by weight, hyaluronic acid 0.5-4 parts by weight, sodium hyaluronate 0.05-0.2 parts by weight, limonene 0.3-0.7 parts by weight, Li It is preferable to include 0.3-3 parts by weight of nalrul and 67-71 parts by weight of broccoli water, and 2-4 parts by weight of Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, 0.5- 1.5 parts by weight, bush clover leaf extract 0.5-1.5 parts by weight, honeysuckle leaf extract 0.5-1.5 parts by weight, bush clover flower extract 0.5-1.5 parts by weight, peony flower extract 0.5-1.5 parts by weight, evening primrose extract 0.5-1.5 parts by weight , sea daffodil oil 0.5-1.5 parts by weight, lavender oil 0.5-1.5 parts by weight, elemental exosomes 0.5-1.5 parts by weight, niacinamide 1-3 parts by weight, arginine 0.5-1.5 parts by weight, adenosine 0.5-1.5 parts by weight, 0.5-1.5 parts by weight of diethylaminohydroxybenzoylhexylbenzoate, 0.5-1.5 parts by weight of triethylhexanoin, 4-6 parts by weight of squalane, 3-5 parts by weight of butylene glycol, 0.08-0.12 parts by weight of propylene glycol 0.08-0.12 parts by weight of polyglyceryl-6 stearate, 0.08-0.12 parts by weight of stearyl alcohol, 0.08-0.12 parts by weight of isoquercitrin, 1-3 parts by weight of hyaluronic acid, 0.08 parts by weight of sodium hyaluronate -0.12 parts by weight, limonene 0.4-0.6 parts by weight, linalool 0.5-1.5 parts by weight and broccoli water 68-70 parts by weight more preferably included.
그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드는 이미 공지된 문헌(대한민국 특허출원 제2005-0098082호) 등에 제시된 펩타이드 성분으로, 본 발명에서는 아토피 개선용 화장료 조성물에 적용하여 효과를 확인할 수 있었다.Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide is a peptide component presented in already known literature (Korean Patent Application No. 2005-0098082), etc., and in the present invention, it is applied to a cosmetic composition for improving atopy so that the effect could be confirmed.
신선초는, 고혈압, 저혈압, 동맥경화, 어께통, 빈혈 등에 효과가 있고, 또 강장, 이뇨, 피부 진정 작용과 항염증, 향균, 알러지 효과에 좋고, 혈액순환 개선으로 피부를 윤택하게 유지해 주는 효과가 있다.Fresh herbs are effective for high blood pressure, low blood pressure, arteriosclerosis, shoulder pain, anemia, etc., and are also good for tonic, diuretic, skin soothing, anti-inflammatory, antibacterial, and allergy effects, and have the effect of keeping the skin moist by improving blood circulation. there is.
싸리나무는 산과 들에서 2~3m의 높이로 흔히 자라고, 7~8월에 꽃이 피는 콩과의 낙엽관목으로, 싸리나무 잎에는 알칼로이드, 플라보노이드, 아스코르빈산이 많이 들어 있고 껍질에는 탄닌이, 껍질과 줄기잎에는 사포닌이 들어 있다. 특히 뿌리껍질에는 알칼로이드가 들어있다. 싸리나무의 잎을 다려서 신장염, 신부전증, 콩팥경화증, 콩팥질소혈증, 등에 쓰고 고혈압 동맥경화를 예방하고 치료하는데 쓸 수 있다. 또한, 싸리나무 잎에는 알칼로이드, 플라보노이드, 아스코드빈산이 많이 들어 있고 껍질에는 탄닌이 들어 있다.Hagi is a deciduous shrub of the leguminous family that grows commonly in mountains and fields at a height of 2 to 3 m, and flowers in July and August. The bark and stem leaves contain saponin. In particular, the root bark contains alkaloids. The leaves of the clover tree can be ironed and used to treat nephritis, renal failure, renal sclerosis, renal azotemia, etc., and to prevent and treat hypertension and arteriosclerosis. In addition, Hagi leaves contain a lot of alkaloids, flavonoids, and ascorbic acid, and the bark contains tannins.
인동덩굴(Lonicera Caprifolium, Honeysuckle)은 금은화 또는 허니서클이라고도 하며 동아시아에 주로 분포한다. 해열, 해독, 항균, 항염증 작용이 있어 염증, 전염성 질환의 치료제로 쓰여 왔다. 본 발명에서는 인동덩굴의 잎을 사용한다.Honeysuckle (Lonicera Caprifolium, Honeysuckle), also known as honeysuckle or honeysuckle, is mainly distributed in East Asia. It has antipyretic, detoxifying, antibacterial, and anti-inflammatory properties, and has been used as a treatment for inflammatory and infectious diseases. In the present invention, honeysuckle leaves are used.
본 발명에서는 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물을 적용하여 아토피성 피부염에 효과적인 우수한 항산화능력과 항균 효과를 나타낼 수 있다.In the present invention, it is possible to exhibit excellent antioxidant ability and antibacterial effect effective for atopic dermatitis by applying the fresh herb leaf extract, clover clover leaf extract and honeysuckle leaf extract.
작약(Paeonia lactiflora, Paeonia albiflora)은 쌍떡잎식물 작약과 작약속의 여러해살이풀로서, 주로 중국을 중심으로 하여 재배되고 있다. 작약의 꽃은 크기가 크고, 색깔이 좋아, 주로 원예용으로만 사용되었으나, 최근 들어 작약의 꽃을 피부 미용 용도로 활용하고자 하는 다양한 시도들이 계속되고 있다.Peony (Paeonia lactiflora, Paeonia albiflora) is a dicotyledonous perennial plant belonging to the peony and peony genus, and is cultivated mainly in China. Peony flowers are large in size and have good color, so they are mainly used only for gardening, but recently, various attempts to use peony flowers for skin care purposes have been continued.
싸리나무꽃을 달인 물로 목욕을 하면 땀을 잘나게 하고 피부 속에 깊이 들어있는 갖가지 노폐물을 몸 밖으로 빠져나오게 하는 효능이 있다. 또한 이를 모아 차로 달여 먹거나 가루내어 먹으면 독특한 풍미를 가진다.Taking a bath with water infused with bush clover flowers has the effect of making you sweat and getting various wastes from the body out of the body. In addition, it has a unique flavor when it is collected and eaten as a tea or powdered.
달맞이꽃에는 우리 몸에서는 생성이 안 되는 감마리놀렌산이 함유되어 있다. 관절염 치료에 탁월한 효능을 가지고 있으며, 프로스타글딘이라는 물질을 조절해서 염증 치료에도 좋다. 혈액순환에도 좋고 항염증작용이 있어 피부의 염증을 억제해 주는 효능이 있다.Evening primrose contains gamma linolenic acid, which our bodies cannot produce. It has excellent efficacy in treating arthritis, and it is also good for treating inflammation by regulating a substance called prostaglandin. It is good for blood circulation and has an anti-inflammatory effect, so it has the effect of suppressing inflammation of the skin.
본 발명에서는 작약꽃 추출물, 싸리나무꽃 추출물 및 달맞이꽃 추출물을 적용하여 아토피성 피부염에 효과적인 우수한 항산화능력과 항균 효과를 나타낼 수 있다.In the present invention, by applying a peony flower extract, a bush clover flower extract, and an evening primrose extract, it is possible to exhibit excellent antioxidant ability and antibacterial effect effective for atopic dermatitis.
바다수선화(Pancratium Maritimum)는 씨대포딜(Sea daffodil)이라고도 불리며 구근식물의 한 종류로 포르투갈의 흑해(Black Sea)와 지중해 연안, 터키, 이스라엘, 시리아 등지에서 자라는 식물이다. 바다 수선화는 해변과 연안의 모래 위에서 자생하는 것이 일반적이다. 본 발명에서는 바다수선화 오일을 적용하여 뛰어난 보습효과와 다크 스팟 감소로 인해 촉촉하고 밝은 피부를 나타내준다.Sea daffodil (Pancratium Maritimum), also called Sea daffodil, is a type of bulbous plant that grows in the Black Sea and Mediterranean coasts of Portugal, Turkey, Israel, and Syria. Sea daffodils are common on beaches and coastal sands. In the present invention, sea daffodil oil is applied to show moist and bright skin due to excellent moisturizing effect and dark spot reduction.
라벤더는 쌍떡잎식물 통화식물목 꿀풀과 라반둘라속에 속하는 25 내지 30종의 식물로, 꽃과 식물체에서 향유를 채취하기 위하여 재배하고 관상용으로도 심는다. 향유는 향수와 화장품의 원료로 사용하고 두통이나 신경안정을 치료하는 데도 쓴다. 라반둘라 오피시날리스(Lavandula officnalis) 또는 라반둘라 안구스티폴리아(Lavandula angustifolis) 종이 주로 아로마 테라피에 사용된다. Lavender is one of 25 to 30 plants belonging to the genus Lamiaceae and Lavender, a dicotyledonous plant, and is cultivated to obtain scented oil from flowers and plants and is also planted for ornamental purposes. Fragrance oil is used as a raw material for perfumes and cosmetics, and is also used to treat headaches or nervous stability. The species Lavandula officnalis or Lavandula angustifolia is mainly used in aromatherapy.
본 발명에서는 바다수선화 오일 및 라벤더 오일을 적용하여 아토피 피부염 진정 효과를 높인다.In the present invention, sea daffodil oil and lavender oil are applied to increase the soothing effect of atopic dermatitis.
소자(Perillae Semen)는 꿀풀과(Labiatae)에 속하는 일년생 초본인 차조기(Perilla frutescens var. acuta)의 과실로서 거담, 변비치료 등의 목적으로 사용된다. 소자(Perillae Semem)는 차조기(소엽)의 씨를 말하는 것으로 발한, 진해, 건위, 이뇨, 진정 및 진통제로 사용한다.Perillae Semen is the fruit of Perilla frutescens var. Soja (Perillae Semem) refers to the seeds of perilla (lobule) and is used as a sweating, antitussive, stomach, diuretic, sedative and analgesic.
본 발명에서는 소자 유래 엑소좀을 적용하여 아토피 피부염 진정 효과를 높인다.In the present invention, the soma-derived exosome is applied to enhance the soothing effect of atopic dermatitis.
나이아신아마이드(niacinamide)는 수용성 비타민B의 복합체로서 니코틴산, 나이아신이라고 명명하기도 하며, 피부의 변색 유도 성분인 멜라닌 세포는 표피층 가장 아래층인 기저층에서 티로시나아제에 의해 생성되며, 이는 기저층에서부터 피부의 표면에 가까운 각질층까지 이동하여 색소침착을 유발하는데, 나이아신아마이드는 이러한 이동을 방해하여 색소침착을 억제할 수 있으며, 각질층에 침착된 색소를 옅게 만들어 피부 미백 효과를 가져올 수 있다. 또한, 나이아신아마이드는 세포간지질의 합성을 증가시켜 피부의 수분 손실방지에 기여할 수도 있다.Niacinamide is a complex of water-soluble vitamin B, and is also named nicotinic acid and niacin. Melanocytes, a component that induces discoloration of the skin, are produced by tyrosinase in the basal layer, the lowest layer of the epidermal layer, which is deposited on the surface of the skin from the basal layer. It moves to the nearby stratum corneum and causes pigmentation. Niacinamide can inhibit pigmentation by interfering with this movement, and it can lighten the pigment deposited in the stratum corneum to bring about a skin whitening effect. In addition, niacinamide may contribute to preventing water loss of the skin by increasing the synthesis of intercellular lipids.
아르기닌(Arginine)은 아토피 피부염 진정 효과와 피부 미백 개선역할을 수행한다.Arginine has a soothing effect on atopic dermatitis and improves skin whitening.
브로콜리는 항산화작용을 가진 베타-카로틴, 루틴, 아스코르빈산, 셀레늄, 케르세틴, 글루타티온 등이 다량 함유되어 있을 뿐만 아니라 칼슘과 비타민C, 엽산 등의 영양 성분도 함유하고 있어 피부 미용에 쓰인다. 본 발명에서는 정제수를 대신하여 브로콜리를 통해 얻은 브로콜리수를 적용함으로써 피부 진정 효과가 더욱 높다.Broccoli contains a large amount of beta-carotene, rutin, ascorbic acid, selenium, quercetin, and glutathione, which have antioxidant effects, as well as nutrients such as calcium, vitamin C, and folic acid, so it is used for skin care. In the present invention, by applying broccoli water obtained through broccoli instead of purified water, the skin soothing effect is higher.
또한, 본 발명에 따른 아토피 개선용 화장료 조성물은 미강 발효추출물을 포함하는 것이 더욱 바람직하다. 상기 미강 발효추출물은 전체 화장료 조성물 100 중량부에 대하여 0.3-3 중량부 포함하는 것이 바람직하고, 0.5-1.5 중량부 포함하는 것이 더욱 바람직하다.In addition, it is more preferable that the cosmetic composition for improving atopy according to the present invention includes a fermented rice bran extract. The fermented rice bran extract is preferably included in an amount of 0.3-3 parts by weight, more preferably 0.5-1.5 parts by weight, based on 100 parts by weight of the total cosmetic composition.
미강은 리파아제(lipase)의 작용이 강하여 지방의 산가가 높아지기 때문에 저장 중 변질되기 쉬우며 기온이 높고 습도가 클 때는 더욱 심하다. 미강의 유효성분을 추출하기 위하여 미강을 미생물 발효시킨 발효 방식에 관한 다양한 연구가 진행되고 있다. 미강 발효추출물은 아스파라트산, 글르타민산, 세린등 여러 가지 아미노산이 풍부하며, 인체의 생리활성물질이 다량 포함하여 몸의 신진대사를 활발하게 해주는 기능성 재료로서 적용된다. 본 발명에서는 아토피 개선 효과에 도움을 준다.Since rice bran has a strong lipase action and increases the acid value of the fat, it is easy to deteriorate during storage, and it is more severe when the temperature is high and the humidity is high. In order to extract the active ingredients of rice bran, various studies are being conducted on fermentation methods in which rice bran is fermented by microorganisms. Rice bran fermented extract is rich in various amino acids such as aspartic acid, glutamic acid, and serine, and contains a large amount of physiologically active substances in the human body, so it is applied as a functional material that activates the body's metabolism. In the present invention, it helps to improve atopy.
또한, 본 발명에 따른 아토피 개선용 화장료 조성물은 진두발 추출물, 대황 추출물, 우뭇가사리 추출물, 청각 추출물 및 톳 추출물을 포함하는 것이 더욱 바람직하다. 상기 진두발 추출물, 대황 추출물, 우뭇가사리 추출물, 청각 추출물 및 톳 추출물은 전체 화장료 조성물 100 중량부에 대하여 각각 0.3-3 중량부 포함하는 것이 바람직하고, 0.5-1.5 중량부 포함하는 것이 더욱 바람직하다.In addition, the cosmetic composition for improving atopy according to the present invention more preferably includes Jindubal extract, rhubarb extract, agar extract, auditoryrrhiza extract and fusiformis extract. The Jindubal extract, rhubarb extract, agar extract, auditory extract, and fusiformis extract are preferably included in an amount of 0.3-3 parts by weight, and more preferably 0.5-1.5 parts by weight, based on 100 parts by weight of the total cosmetic composition.
진두발(Chondrus ocellatus)은 몸길이 5~2-cm의 엽상체로 짙은 보라색이다. 줄기는 짧은 거리에서 여러 차례 두 갈래로 가지를 내며 단추 모양의 뿌리에서 짧은 줄기가 나오고 이 줄기가 넓어지면서 부채모양으로 펼쳐진다. 파도의 영향이 많은 조간대 하부에서 암반에 주로 생육하며 우리나라 전국 연안에 분포한다.Chondrus ocellatus is a dark purple frond with a body length of 5-2 cm. The stem branches into two branches several times at a short distance, and a short stem comes out from the button-shaped root, and this stem spreads out in a fan shape as it widens. It grows mainly on bedrock in the lower intertidal zone, where there is a lot of influence from waves, and is distributed all over the coast of Korea.
대황(Eisenia bicyclis)은 갈조류의 식용 해조류로 phlorotannins과 같은 생리활성 물질을 다량 함유하고 있으며, 대황으로부터 분리된 항산화 활성을 지닌 phlorotannins에는 eckol, phlorofucofuroeckol-A, dieckol 그리고 8,8′-bieckol 등이 보고되고 있다. 또한, 대황의 phlorotannins은 항균, 항염증, 항고지혈증 및 항당뇨 등의 다양한 생리활성을 가지고 있다고 보고되어 있다.Rhubarb (Eisenia bicyclis) is an edible seaweed of brown algae that contains a large amount of physiologically active substances such as phlorotannins, and eckol, phlorofucofuroeckol-A, dieckol, and 8,8′-bieckol have been reported as phlorotannins isolated from rhubarb that have antioxidant activity. It is becoming. In addition, it has been reported that rhubarb phlorotannins have various physiological activities such as antibacterial, anti-inflammatory, antihyperlipidemic and antidiabetic.
우뭇가사리(Gelidium amansii)는 우뭇가사리과에 속하는 홍조류의 해조류이다. 바닷말의 일종으로 주로 한천의 주원료로 이용되는 바닷말을 가리킨다. 여러해살이 해조류로서 여름의 번식기가 지나면 본체의 상부는 녹아 없어지고 하부만 남아 있다가 다음해 봄에 다시 새싹이 자라난다. 동해안·남해안과 황해의 바깥 도서에 분포하나 동해 남부 연안의 것이 품질도 좋고 가장 많이 생산된다. 바닷속 20-30m 깊이의 바위에 붙어 자라는데, 바깥바다에 면하고 바닥이 모래로 되어 있으며, 해수의 소통이 잘되는 곳에 산다.Agar-agar (Gelidium amansii) is a type of red algae belonging to the family Agaraceae. It is a type of seaweed and refers to seaweed that is mainly used as the main raw material for agar. As a perennial seaweed, after the breeding season in summer, the upper part of the main body melts away and only the lower part remains, and new sprouts grow again in the spring of the following year. It is distributed in the east coast, the south coast and the outer islands of the Yellow Sea, but the ones in the southern coast of the East Sea are of good quality and are produced the most. It grows attached to a rock at a depth of 20-30m in the sea, and lives in a place with a sandy bottom and good communication with seawater.
청각(Codium fragile, green fleece, green sea fingers, stag · sponge seaweed)은 청각과의 청각속에 속하는 조류이다. 청각의 몸 표면에는 '소낭'이라는 대롱 모양의 작은 주머니가 배열되어 있어서 피층을 이루며, 한편 소낭의 밑부분에서부터 뻗은 가지들이 서로 얽혀서 속부분을 만든다. 이 때 몸 전체는 격벽이 없이 하나의 세포로 이루어져 있으므로, '비세포성 체제'라고 부르기도 한다. 청각은 세계 각지의 연안에 분포하며, 특히 간조선 부근의 암초에 잘 발달되어 있다. 청각 무리에는 많은 종류가 있는데, 중요한 종류로는 구슬청각·밀청각·말청각 등이 있다.Codium fragile, green fleece, green sea fingers, stag · sponge seaweed) is an alga belonging to the hearing genus of the hearing family. On the surface of the auditory body, small tube-shaped pockets called 'follicles' are arranged to form the cortex, while the branches extending from the bottom of the follicles are intertwined to form the inner part. At this time, the entire body is made up of one cell without a septum, so it is also called the 'non-cellular system'. The auditory sense is distributed on the coasts of all parts of the world, and is especially well developed in the reefs near the tidal line. There are many types of auditory groups, the important ones being bead hearing, wheat hearing, and speech hearing.
톳(hijiki)은 바닷말의 일종으로, 갈색말 무리에 속한다. 칼슘, 요오드, 철, 마그네슘 등이 매우 풍부하다. 또한 톳은 한국, 일본, 중국 등지에서 암초 위에 살고 있다. 톳은 조간대 하부에서 큰 군락을 이룬다. 식물체는 섬유상의 뿌리를 가지고 직립하며, 줄기는 원주상이고 1회 우상으로 가지가 갈라지며 보통 10∼60cm 이상 자란다. 가지 중 작은 것은 곤봉 모양을 하며 얼핏 보아 잎과 같이 느껴진다. 청정해 완도및 서남해(남해안일대)에서 자연산과 양식으로 생산되는 갈조식물이다. 톳에는 칼슘, 철, 인, 요소 등의 미네날과 식이섬유가 풍부하다. Hijiki is a type of sea horse and belongs to the brown horse group. It is very rich in calcium, iodine, iron and magnesium. It also lives on reefs in Korea, Japan, and China. Hijiki forms large colonies in the lower intertidal zone. The plant is erect with fibrous roots, and the stem is columnar and branches once pinnately, usually growing more than 10 to 60 cm. The small one of the branches is shaped like a club and at first glance it feels like a leaf. It is a brown algae plant produced in the wild and aquaculture in the clean Wando and the southwest sea (Southern Coast area). Hijiki is rich in minerals and dietary fiber, such as calcium, iron, phosphorus, and urea.
상기 진두발 추출물, 대황 추출물, 우뭇가사리 추출물, 청각 추출물 및 톳 추출물을 포함하여 아토피 개선 효과에 도움을 준다.Including the Jindubal extract, rhubarb extract, agar-agar extract, hearing extract and fusiformis extract, it helps to improve atopic dermatitis.
또한, 본 발명은In addition, the present invention
신선초잎, 싸리나무잎 및 인동덩굴잎을 세척하고 동결건조한 후 분쇄하여 신선초잎분말, 싸리나무잎분말 및 인동덩굴잎분말을 준비하는 단계; 준비된 신선초잎분말, 싸리나무잎분말 및 인동덩굴잎분말을 1:1:1의 중량비율로 혼합한 혼합분말을 에탄올 및 헥산을 1:1의 부피비로 혼합한 혼합 용매와 1:9의 중량비율로 혼합하고, 28-32℃의 온도에서 22-26시간 동안 추출하여 추출액을 제조하는 단계; 및 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 50℃에서 감압농축 및 동결건조하는 단계;를 포함하는 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물을 제조하는 단계;Preparing fresh herb leaf powder, clover clover leaf powder, and honeysuckle leaf powder by washing, freeze-drying, and pulverizing fresh herb leaves, clover clover leaf and honeysuckle leaf; Prepared fresh herb leaf powder, clover leaf powder and honeysuckle leaf powder were mixed in a weight ratio of 1: 1: 1, and a mixed solvent in which ethanol and hexane were mixed in a volume ratio of 1: 1 and a weight ratio of 1: 9 preparing an extract by mixing and extracting at a temperature of 28-32 ° C for 22-26 hours; and filtering the extract with a filter paper, concentrating the filtered filtrate under reduced pressure and freeze-drying the filtrate at minus 50 ° C.
싸리나무꽃, 작약꽃 및 달맞이꽃을 세척하고 동결건조한 후 분쇄하여 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 제조하는 단계; 제조된 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 1:1:1의 중량비율로 혼합한 혼합분말 20 g을 물 200 ml와 혼합하고, 교반하면서 80℃의 온도에서 8시간 동안 1차 열수추출을 수행하는 단계; 1차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 1차 혼합추출물을 제조하는 단계; 1차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 교반하면서 120℃의 온도에서 12시간 동안 2차 열수추출을 수행하는 단계; 2차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 2차 혼합추출물을 제조하는 단계; 2차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 여기에 [BMIm][TFSI](1-Butyl-3-methylimidazoliumbis trifluoromethylsulfonyl)imide)를 1-2 g 첨가한 후 교반하면서 100℃의 온도에서 8시간 동안 3차 열수추출을 수행하는 단계; 3차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 3차 혼합추출물을 제조하는 단계; 및 상기 1차 혼합추출물, 2차 혼합추출물 및 3차 혼합추출물을 혼합하는 단계;를 포함하는 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물을 제조하는 단계;Preparing clover flower powder, peony flower powder, and evening primrose powder by washing, freeze-drying, and pulverizing clover flower, peony flower, and evening primrose; 20 g of the prepared mixed powder of clover flower powder, peony flower powder, and evening primrose powder mixed in a weight ratio of 1:1:1 was mixed with 200 ml of water, followed by primary hot water at 80°C for 8 hours while stirring. performing an extraction; After the first hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a first mixed extract; After the first hot water extraction, the remaining solids were filtered with filter paper, and the remaining solids were mixed with water so that the mixing ratio of the solids and water was 0.1 g/ml, and the second hot water extraction was performed at a temperature of 120 ° C for 12 hours while stirring. doing; After secondary hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a secondary mixed extract; After the second hot water extraction, filter with filter paper, and mix the remaining solids with water again so that the mixing ratio of solids and water is 0.1 g/ml, and [BMIm][TFSI](1-Butyl-3-methylimidazolium After adding 1-2 g of trifluoromethylsulfonyl)imide), performing a third hot water extraction at a temperature of 100 ° C. for 8 hours while stirring; After tertiary hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a tertiary mixed extract; And mixing the first mixed extract, the second mixed extract and the tertiary mixed extract; preparing a bush clover flower extract, a peony flower extract and an evening primrose extract containing;
바다수선화 및 라벤더를 분쇄하여 바다수선화분말 및 라벤더분말을 준비하는 단계; 상기 바다수선화분말 및 라벤더분말을 1:1의 중량비율로 혼합한 혼합분말 및 헥산을 혼합하고, 33-37℃의 온도에서 2-4일 동안 교반하여 추출물을 제조하는 단계; 및 상기 추출물을 여과하고 감압농축한 후 원심분리하여 이물질을 제거한 후, 감압증류하는 단계;를 포함하는 바다수선화 오일 및 라벤더 오일을 제조하는 단계;Preparing sea daffodil powder and lavender powder by crushing sea daffodil and lavender; preparing an extract by mixing a mixture of daffodil powder and lavender powder in a weight ratio of 1:1 with hexane and stirring at a temperature of 33-37 ° C. for 2-4 days; Preparing sea daffodil oil and lavender oil comprising; filtering and concentrating the extract under reduced pressure, centrifuging to remove foreign substances, and distilling under reduced pressure;
소자를 세척하여 28-32℃의 온도에서 290-310 MPa의 압력으로 1-5분 동안 전처리하는 단계; 전처리된 소자를 착즙하여 소자 착즙액을 제조하는 단계; 상기 소자 착즙액을 원심분리하여 엑소좀을 포함하는 상층액을 수득하는 단계; 상기 엑소좀을 포함하는 상층액을 동결건조하여 동결건조물을 제조하는 단계; 상기 동결건조물에 폴리에틸렌글리콜/덱스트란을 사용하여 수성 2상계를 형성하는 단계; 및 상기 수성 2상계 내 엑소좀이 농축된 하층액을 수득하는 단계;를 포함하는 소자 유래 엑소좀을 제조하는 단계;washing the device and pre-treating it at a temperature of 28-32° C. and a pressure of 290-310 MPa for 1-5 minutes; Preparing a device juice by extracting the pretreated device; Obtaining a supernatant containing exosomes by centrifuging the juice from the cow; preparing a lyophilisate by freeze-drying the supernatant containing the exosomes; forming an aqueous two-phase system using polyethylene glycol/dextran in the lyophilisate; and obtaining an exosome-enriched lower layer in the aqueous two-phase system; preparing a device-derived exosome comprising;
그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 1-5 중량부, 상기에서 제조된 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물 1-5 중량부, 상기에서 제조된 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물 1-5 중량부, 상기에서 제조된 소자 유래 엑소좀 0.3-3 중량부, 나이아신아마이드 0.5-4 중량부, 아르기닌 0.3-3 중량부, 아데노신 0.3-3 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.3-3 중량부, 트라이에틸헥사노인 0.3-3 중량부, 스테아릴알코올 0.05-0.2 중량부, 이소퀘르시트린 0.05-0.2 중량부, 하이알루로닉애씨드 0.5-4 중량부, 소듐하이알루로네이트 0.05-0.2 중량부, 리모넨 0.3-0.7 중량부, 리날룰 0.3-3 중량부 및 브로콜리수 47-51 중량부를 혼합하고, 68-72℃의 온도에서 28-32분 동안 교반하여 제1 혼합조성물을 제조하는 단계;1-5 parts by weight of Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, 1-5 parts by weight of the above-prepared cinnamon leaf extract, clover clover leaf extract and honeysuckle leaf extract, 1-5 parts by weight of Hsagi flower extract, peony flower extract and evening primrose extract prepared above, 0.3-3 parts by weight of the device-derived exosome prepared above, 0.5-4 parts by weight of niacinamide, 0.3-3 parts by weight of arginine, 0.3 parts by weight of adenosine -3 parts by weight, diethylaminohydroxybenzoylhexylbenzoate 0.3-3 parts by weight, triethylhexanoin 0.3-3 parts by weight, stearyl alcohol 0.05-0.2 parts by weight, isoquercitrin 0.05-0.2 parts by weight, hyaluronic acid 0.5-4 parts by weight of rhonic acid, 0.05-0.2 parts by weight of sodium hyaluronate, 0.3-0.7 parts by weight of limonene, 0.3-3 parts by weight of linalool and 47-51 parts by weight of broccoli water were mixed, and Stirring for 28-32 minutes at a temperature to prepare a first mixed composition;
상기에서 제조된 바다수선화 오일 및 라벤더 오일 0.5-4 중량부, 스쿠알란 3-7 중량부, 부틸렌글라이콜 2-6 중량부, 프로필렌글라이콜 0.05-0.2 중량부, 폴리글리세릴-6스테아레이트 0.05-0.2 중량부 및 브로콜리수 18-22 중량부를 혼합하고, 38-42℃의 온도에서 58-62분 동안 교반하여 제2 혼합조성물을 제조하는 단계; 및0.5-4 parts by weight of daffodil oil and lavender oil prepared above, 3-7 parts by weight of squalane, 2-6 parts by weight of butylene glycol, 0.05-0.2 parts by weight of propylene glycol, polyglyceryl-6 stearate Preparing a second mixed composition by mixing 0.05-0.2 parts by weight and 18-22 parts by weight of broccoli water and stirring at a temperature of 38-42 ° C. for 58-62 minutes; and
상기 제1 혼합조성물 및 상기 제2 혼합조성물을 혼합하고, 48-52℃의 온도에서 18-22분 동안 교반하는 단계;를 포함하는 아토피 개선용 화장료 조성물의 제조방법을 제공한다.It provides a method for producing a cosmetic composition for improving atopic dermatitis, comprising: mixing the first mixed composition and the second mixed composition and stirring for 18-22 minutes at a temperature of 48-52 ° C.
이때, 도 1에 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법을 순서도로 나타내었으며, 이하, 도 1을 참조하여 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법을 각 단계별로 상세히 설명한다.At this time, the manufacturing method of the cosmetic composition for improving atopy according to the present invention is shown in a flowchart in Figure 1, and the manufacturing method of the cosmetic composition for improving atopy according to the present invention according to the present invention will be described in detail with reference to FIG.
먼저, 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법은 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물을 제조하는 단계를 포함한다. 상기 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물을 제조하는 단계는, 신선초잎, 싸리나무잎 및 인동덩굴잎을 세척하고 동결건조한 후 분쇄하여 신선초잎분말, 싸리나무잎분말 및 인동덩굴잎분말을 준비하는 단계; 준비된 신선초잎분말, 싸리나무잎분말 및 인동덩굴잎분말을 1:1:1의 중량비율로 혼합한 혼합분말을 에탄올 및 헥산을 1:1의 부피비로 혼합한 혼합 용매와 1:9의 중량비율로 혼합하고, 28-32℃의 온도에서 22-26시간 동안 추출하여 추출액을 제조하는 단계; 및 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 50℃에서 감압농축 및 동결건조하는 단계;를 포함한다.First, the method for preparing a cosmetic composition for improving atopy according to the present invention includes the steps of preparing an extract of fresh grass leaves, an extract of Hsalt japonica leaves, and an extract of honeysuckle leaves. In the step of preparing the fresh herb leaf extract, clover clover leaf extract and honeysuckle leaf extract, the fresh herb leaf, clover clover leaf and honeysuckle leaf are washed, freeze-dried, and then pulverized to obtain fresh herb leaf powder, clover clover leaf powder and honeysuckle leaf. preparing the powder; Prepared fresh herb leaf powder, clover leaf powder and honeysuckle leaf powder were mixed in a weight ratio of 1: 1: 1, and a mixed solvent in which ethanol and hexane were mixed in a volume ratio of 1: 1 and a weight ratio of 1: 9 preparing an extract by mixing and extracting at a temperature of 28-32 ° C for 22-26 hours; and filtering the extract with a filter paper, and concentrating and lyophilizing the filtered filtrate at -50 °C under reduced pressure.
상기 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물은 에탄올 및 헥산을 1:1의 부피비로 혼합한 혼합 용매를 적용한 추출방법으로 추출함으로써 항산화성분을 용이하게 추출할 수 있다.Antioxidants can be easily extracted from the fresh herb leaf extract, clover clover leaf extract, and honeysuckle leaf extract by an extraction method using a mixed solvent in which ethanol and hexane are mixed in a volume ratio of 1:1.
다음으로, 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법은 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물을 제조하는 단계를 포함한다. 상기 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물을 제조하는 단계는, 싸리나무꽃, 작약꽃 및 달맞이꽃을 세척하고 동결건조한 후 분쇄하여 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 제조하는 단계; 제조된 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 1:1:1의 중량비율로 혼합한 혼합분말 20 g을 물 200 ml와 혼합하고, 교반하면서 80℃의 온도에서 8시간 동안 1차 열수추출을 수행하는 단계; 1차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 1차 혼합추출물을 제조하는 단계; 1차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 교반하면서 120℃의 온도에서 12시간 동안 2차 열수추출을 수행하는 단계; 2차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 2차 혼합추출물을 제조하는 단계; 2차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 여기에 [BMIm][TFSI](1-Butyl-3-methylimidazoliumbis trifluoromethylsulfonyl)imide)를 1-2 g 첨가한 후 교반하면서 100℃의 온도에서 8시간 동안 3차 열수추출을 수행하는 단계; 3차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 3차 혼합추출물을 제조하는 단계; 및 상기 1차 혼합추출물, 2차 혼합추출물 및 3차 혼합추출물을 혼합하는 단계;를 포함한다.Next, the method for preparing the cosmetic composition for improving atopy according to the present invention includes preparing a clover flower extract, a peony flower extract, and an evening primrose extract. The step of preparing the clover clover flower extract, peony flower extract, and evening primrose extract includes washing, freeze-drying, and pulverizing clover clover flower powder, peony flower powder, and evening primrose flower powder, peony flower powder, and evening primrose flower powder; 20 g of the prepared mixed powder of clover flower powder, peony flower powder, and evening primrose powder mixed in a weight ratio of 1:1:1 was mixed with 200 ml of water, followed by primary hot water at 80°C for 8 hours while stirring. performing an extraction; After the first hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a first mixed extract; After the first hot water extraction, the remaining solids were filtered with filter paper, and the remaining solids were mixed with water so that the mixing ratio of the solids and water was 0.1 g/ml, and the second hot water extraction was performed at a temperature of 120 ° C for 12 hours while stirring. doing; After secondary hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a secondary mixed extract; After the second hot water extraction, filter with filter paper, and mix the remaining solids with water again so that the mixing ratio of solids and water is 0.1 g/ml, and [BMIm][TFSI](1-Butyl-3-methylimidazolium After adding 1-2 g of trifluoromethylsulfonyl)imide), performing a third hot water extraction at a temperature of 100 ° C. for 8 hours while stirring; After tertiary hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a tertiary mixed extract; and mixing the first mixed extract, the second mixed extract and the tertiary mixed extract.
상기 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물은 다단계 열수추출 공정으로 제조하는 것이 바람직하며, 각 꽃의 유효성분을 손상없이 추출할 수 있다.The Hsagi flower extract, peony flower extract, and evening primrose extract are preferably prepared by a multi-step hot water extraction process, and the active ingredients of each flower can be extracted without damage.
다음으로, 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법은 바다수선화 오일 및 라벤더 오일을 제조하는 단계를 포함한다. 상기 바다수선화 오일 및 라벤더 오일을 제조하는 단계는, 바다수선화 및 라벤더를 분쇄하여 바다수선화분말 및 라벤더분말을 준비하는 단계; 상기 바다수선화분말 및 라벤더분말을 1:1의 중량비율로 혼합한 혼합분말 및 헥산을 혼합하고, 33-37℃의 온도에서 2-4일 동안 교반하여 추출물을 제조하는 단계; 및 상기 추출물을 여과하고 감압농축한 후 원심분리하여 이물질을 제거한 후, 감압증류하는 단계;를 포함한다.Next, the method for preparing the cosmetic composition for improving atopy according to the present invention includes preparing daffodil oil and lavender oil. The step of preparing daffodil oil and lavender oil may include preparing daffodil powder and lavender powder by pulverizing daffodil and lavender; preparing an extract by mixing a mixture of daffodil powder and lavender powder in a weight ratio of 1:1 with hexane and stirring at a temperature of 33-37 ° C. for 2-4 days; And filtering the extract, concentrating under reduced pressure, centrifuging to remove foreign substances, and then distilling under reduced pressure.
다음으로, 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법은 소자 유래 엑소좀을 제조하는 단계를 포함한다. 상기 소자 유래 엑소좀을 제조하는 단계는, 소자를 세척하여 28-32℃의 온도에서 290-310 MPa의 압력으로 1-5분 동안 전처리하는 단계; 전처리된 소자를 착즙하여 소자 착즙액을 제조하는 단계; 상기 소자 착즙액을 원심분리하여 엑소좀을 포함하는 상층액을 수득하는 단계; 상기 엑소좀을 포함하는 상층액을 동결건조하여 동결건조물을 제조하는 단계; 상기 동결건조물에 폴리에틸렌글리콜/덱스트란을 사용하여 수성 2상계를 형성하는 단계; 및 상기 수성 2상계 내 엑소좀이 농축된 하층액을 수득하는 단계;를 포함한다.Next, the method for preparing the cosmetic composition for improving atopy according to the present invention includes preparing a device-derived exosome. The step of preparing the device-derived exosome may include washing the device and pre-treating the device at a temperature of 28-32° C. and a pressure of 290-310 MPa for 1-5 minutes; Preparing a device juice by extracting the pretreated device; Obtaining a supernatant containing exosomes by centrifuging the juice from the cow; preparing a lyophilisate by freeze-drying the supernatant containing the exosomes; forming an aqueous two-phase system using polyethylene glycol/dextran in the lyophilisate; and obtaining a lower layer in which exosomes are concentrated in the aqueous two-phase system.
다음으로, 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법은 그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 1-5 중량부, 상기에서 제조된 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물 1-5 중량부, 상기에서 제조된 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물 1-5 중량부, 상기에서 제조된 소자 유래 엑소좀 0.3-3 중량부, 나이아신아마이드 0.5-4 중량부, 아르기닌 0.3-3 중량부, 아데노신 0.3-3 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.3-3 중량부, 트라이에틸헥사노인 0.3-3 중량부, 스테아릴알코올 0.05-0.2 중량부, 이소퀘르시트린 0.05-0.2 중량부, 하이알루로닉애씨드 0.5-4 중량부, 소듐하이알루로네이트 0.05-0.2 중량부, 리모넨 0.3-0.7 중량부, 리날룰 0.3-3 중량부 및 브로콜리수 47-51 중량부를 혼합하고, 68-72℃의 온도에서 28-32분 동안 교반하여 제1 혼합조성물을 제조하는 단계를 포함한다.Next, the method for producing a cosmetic composition for improving atopy according to the present invention is Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide 1-5 parts by weight, fresh grass leaf extract prepared above, Hsari 1-5 parts by weight of tree leaf extract and honeysuckle leaf extract, 1-5 parts by weight of clover flower extract, peony flower extract and evening primrose extract prepared above, 0.3-3 parts by weight of exosomes derived from the above-prepared device, niacin 0.5-4 parts by weight of amide, 0.3-3 parts by weight of arginine, 0.3-3 parts by weight of adenosine, 0.3-3 parts by weight of diethylaminohydroxybenzoylhexylbenzoate, 0.3-3 parts by weight of triethylhexanoin, 0.05 parts by weight of stearyl alcohol -0.2 parts by weight, isoquercitrin 0.05-0.2 parts by weight, hyaluronic acid 0.5-4 parts by weight, sodium hyaluronate 0.05-0.2 parts by weight, limonene 0.3-0.7 parts by weight, linalool 0.3-3 parts by weight and preparing a first mixed composition by mixing 47-51 parts by weight of broccoli water and stirring at a temperature of 68-72° C. for 28-32 minutes.
상기 단계에서는 GsMTx4 펩타이드와, 신선초잎 추출물 등을 혼합하되, 상대적 고온에서 교반하여 제1 혼합조성물을 제조한다.In the above step, the first mixed composition is prepared by mixing the GsMTx4 peptide and the fresh grass leaf extract, etc., and stirring at a relatively high temperature.
상기 제1 혼합조성물은 미강 발효추출물을 0.3-3 중량부 포함하는 것이 바람직하고, 0.5-1.5 중량부 포함하는 것이 더욱 바람직하다.The first mixed composition preferably contains 0.3-3 parts by weight of rice bran fermented extract, more preferably 0.5-1.5 parts by weight.
상기 미강 발효추출물은, 미강을 끓인 물로 세척하고, 분쇄하여 미강분말을 준비하는 단계; 미강분말 및 물을 혼합한 혼합물에 효모균으로 사카로미케스 케레비시아이(Saccharomyces cerevisiae)를 첨가한 후 33-37℃의 온도에서 22-26시간 동안 발효시키는 단계; 발효된 혼합물 및 부틸렌글리콜을 혼합하고, 28-32℃의 온도에서 6-8일 동안 교반하여 추출물을 제조하는 단계; 및 상기 추출물을 여과 및 감압농축한 후 동결건조하는 단계;를 수행하여 제조되는 것을 사용한다.Preparing rice bran powder by washing the fermented rice bran extract with boiled water and pulverizing the rice bran; Adding Saccharomyces cerevisiae as a yeast to a mixture of rice bran powder and water, followed by fermentation at a temperature of 33-37 ° C. for 22-26 hours; Preparing an extract by mixing the fermented mixture and butylene glycol and stirring at a temperature of 28-32 ° C. for 6-8 days; and lyophilizing the extract after filtering and concentrating under reduced pressure.
상기 제1 혼합조성물은 진두발 추출물 0.3-3 중량부, 대황 추출물 0.3-3 중량부, 우뭇가사리 추출물 0.3-3 중량부, 청각 추출물 0.3-3 중량부 및 톳 추출물 0.3-3 중량부를 포함하는 것이 바람직하고, 진두발 추출물 0.5-1.5 중량부, 대황 추출물 0.5-1.5 중량부, 우뭇가사리 추출물 0.5-1.5 중량부, 청각 추출물 0.5-1.5 중량부 및 톳 추출물 0.5-1.5 중량부를 포함하는 것이 더욱 바람직하다.Preferably, the first mixed composition includes 0.3-3 parts by weight of Jindubal extract, 0.3-3 parts by weight of rhubarb extract, 0.3-3 parts by weight of agar extract, 0.3-3 parts by weight of auditory extract, and 0.3-3 parts by weight of fusiformis extract. And, it is more preferable to include 0.5-1.5 parts by weight of Jindubal extract, 0.5-1.5 parts by weight of rhubarb extract, 0.5-1.5 parts by weight of agar extract, 0.5-1.5 parts by weight of auditory extract, and 0.5-1.5 parts by weight of fusiformis extract.
상기 진두발 추출물, 대황 추출물, 우뭇가사리 추출물, 청각 추출물 및 톳 추출물은, 진두발, 대황, 우뭇가사리, 청각 및 톳을 세척하고 적절한 크기로 절단하여 준비하는 단계; 세척된 진두발, 대황, 우뭇가사리, 청각 및 톳을 1:1:1:1:1의 중량비율로 혼합 및 분쇄하여 원료분말을 얻고, 상기 원료분말 8-12 중량부 및 물 88-92 중량부를 혼합한 혼합물을 92-95℃의 온도로 가열하고, 증발하는 증기를 냉각시켜 얻은 증류액이 다시 혼합물에 혼합되도록 하여 90-150분 동안 순환시키는 단계; 상기 순환이 완료된 혼합물을 98-100℃의 온도로 가열하고, 150-210분 동안 증발하는 증기를 냉각시켜 1차 추출액을 얻는 단계; 상기 혼합물의 고형분을 얻어 에탄올과 혼합한 후 48-52℃의 온도에서 2-6시간 동안 추출하여 2차 추출액을 얻는 단계; 및 상기 제1 추출액 및 제2 추출액을 감압농축한 후 동결건조 및 분쇄하는 단계;를 수행하여 제조되는 것을 사용한다.The step of preparing the Jindubal extract, rhubarb extract, agar-agar extract, auditory extract and fusiformis extract by washing Jindubal, rhubarb, agar-agar, and cutting into appropriate sizes; Raw material powder was obtained by mixing and pulverizing washed jindubal, rhubarb, agar-agar, sage and fusiformis in a weight ratio of 1: 1: 1: 1: 1, and 8-12 parts by weight of the raw material powder and 88-92 parts by weight of water Heating the mixed mixture to a temperature of 92-95° C., cooling the evaporating vapor, and mixing the distillate with the mixture again to circulate for 90-150 minutes; obtaining a primary extract by heating the cycled mixture to a temperature of 98-100° C. and cooling the evaporating vapor for 150-210 minutes; Obtaining a solid content of the mixture, mixing it with ethanol, and then extracting at a temperature of 48-52 ° C. for 2-6 hours to obtain a secondary extract; and concentrating the first extract and the second extract under reduced pressure, followed by lyophilization and pulverization.
다음으로, 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법은 상기에서 제조된 바다수선화 오일 및 라벤더 오일 0.5-4 중량부, 스쿠알란 3-7 중량부, 부틸렌글라이콜 2-6 중량부, 프로필렌글라이콜 0.05-0.2 중량부, 폴리글리세릴-6스테아레이트 0.05-0.2 중량부 및 브로콜리수 18-22 중량부를 혼합하고, 38-42℃의 온도에서 58-62분 동안 교반하여 제2 혼합조성물을 제조하는 단계를 포함한다.Next, the method for producing the cosmetic composition for improving atopy according to the present invention includes 0.5-4 parts by weight of daffodil oil and lavender oil prepared above, 3-7 parts by weight of squalane, 2-6 parts by weight of butylene glycol, propylene 0.05-0.2 parts by weight of glycol, 0.05-0.2 parts by weight of polyglyceryl-6 stearate, and 18-22 parts by weight of broccoli water were mixed and stirred at a temperature of 38-42 ° C. for 58-62 minutes to obtain a second mixed composition It includes the step of manufacturing.
상기 단계에서는 바다수선화 오일 및 라벤더 오일, 스쿠알란 등의 성분을 혼합하되, 상대적 저온에서 교반하여 제2 혼합조성물을 제조한다.In the above step, ingredients such as sea daffodil oil, lavender oil, and squalane are mixed, but stirred at a relatively low temperature to prepare a second mixed composition.
다음으로, 본 발명에 따른 아토피 개선용 화장료 조성물의 제조방법은 상기 제1 혼합조성물 및 상기 제2 혼합조성물을 혼합하고, 48-52℃의 온도에서 18-22분 동안 교반하는 단계를 포함한다.Next, the manufacturing method of the cosmetic composition for improving atopy according to the present invention includes mixing the first mixed composition and the second mixed composition, and stirring at a temperature of 48-52 ° C. for 18-22 minutes.
최종적으로 제1 혼합조성물 및 제2 혼합조성물을 혼합 및 교반하여 미백 화장료 조성물을 제조한다.Finally, a whitening cosmetic composition is prepared by mixing and stirring the first mixed composition and the second mixed composition.
이하, 본 발명을 하기의 실시예에 의해 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail by the following examples.
단, 하기 실시예는 본 발명의 내용을 예시하는 것일 뿐 발명의 범위가 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following examples are merely illustrative of the content of the present invention, but the scope of the invention is not limited by the examples and experimental examples.
<제조예 1> 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물의 제조<Preparation Example 1> Preparation of fresh herb leaf extract, clover clover leaf extract and honeysuckle leaf extract
신선초잎, 싸리나무잎 및 인동덩굴잎을 세척하고 동결건조한 후 분쇄하여 신선초잎분말, 싸리나무잎분말 및 인동덩굴잎분말을 준비하였다. 준비된 신선초잎분말, 싸리나무잎분말 및 인동덩굴잎분말을 1:1:1의 중량비율로 혼합한 혼합분말을 에탄올 및 헥산을 1:1의 부피비로 혼합한 혼합 용매와 1:9의 중량비율로 혼합하고, 30℃의 온도에서 24시간 동안 추출하여 추출액을 제조하였다. 상기 추출액을 여과지로 여과하고, 여과된 여과액을 영하 50℃에서 감압농축 및 동결건조하여 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물을 제조하였다.Fresh herb leaves, clover clover leaves and honeysuckle leaves were washed, freeze-dried, and pulverized to prepare fresh herb leaf powder, clover clover leaf powder, and honeysuckle leaf powder. Prepared fresh herb leaf powder, clover leaf powder and honeysuckle leaf powder were mixed in a weight ratio of 1: 1: 1, and a mixed solvent in which ethanol and hexane were mixed in a volume ratio of 1: 1 and a weight ratio of 1: 9 , and extracted for 24 hours at a temperature of 30 ° C. to prepare an extract. The extract was filtered with a filter paper, and the filtered filtrate was concentrated under reduced pressure and lyophilized at -50° C. to prepare an extract of cinnamon plant leaf, clover clover leaf extract, and honeysuckle leaf extract.
<제조예 2> 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물의 제조<Preparation Example 2> Preparation of clover flower extract, peony flower extract and evening primrose extract
싸리나무꽃, 작약꽃 및 달맞이꽃을 세척하고 동결건조한 후 분쇄하여 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 제조한 후, 제조된 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 1:1:1의 중량비율로 혼합한 혼합분말 20 g을 물 200 ml와 혼합하고, 교반하면서 80℃의 온도에서 8시간 동안 1차 열수추출을 수행하였다. 1차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 1차 혼합추출물을 제조하였다.After washing clover flower, peony flower, and evening primrose, freeze-drying, and pulverizing to prepare clover flower powder, peony flower powder, and evening primrose powder, the prepared clover flower powder, peony flower powder, and evening primrose powder were prepared 1:1: 20 g of the mixed powder mixed at a weight ratio of 1 was mixed with 200 ml of water, and primary hot water extraction was performed at a temperature of 80° C. for 8 hours while stirring. After the first hot water extraction, the mixture was filtered with filter paper, and the filtrate was freeze-dried to prepare a first mixed extract.
1차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 교반하면서 120℃의 온도에서 12시간 동안 2차 열수추출을 수행하였다. 2차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 2차 혼합추출물을 제조하였다.After the first hot water extraction, the remaining solids were filtered with filter paper, and the remaining solids were mixed with water so that the mixing ratio of the solids and water was 0.1 g/ml, and the second hot water extraction was performed at a temperature of 120 ° C for 12 hours while stirring. did After the second hot water extraction, the mixture was filtered with filter paper, and the filtrate was freeze-dried to prepare a second mixed extract.
2차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 여기에 [BMIm][TFSI](1-Butyl-3-methylimidazoliumbis trifluoromethylsulfonyl)imide)를 1.5 g 첨가한 후 교반하면서 100℃의 온도에서 8시간 동안 3차 열수추출을 수행하였다. 3차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 3차 혼합추출물을 제조하였다. After the second hot water extraction, filter with filter paper, and mix the remaining solids with water again so that the mixing ratio of solids and water is 0.1 g/ml, and [BMIm][TFSI](1-Butyl-3-methylimidazolium After adding 1.5 g of trifluoromethylsulfonyl)imide), tertiary hot water extraction was performed at a temperature of 100° C. for 8 hours while stirring. After the tertiary hot water extraction, the mixture was filtered with a filter paper, and the filtrate was freeze-dried to prepare a tertiary mixed extract.
상기 1차 혼합추출물, 2차 혼합추출물 및 3차 혼합추출물을 혼합하여 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물을 제조하였다.The first mixed extract, the second mixed extract, and the tertiary mixed extract were mixed to prepare a clover flower extract, a peony flower extract, and an evening primrose extract.
<제조예 3> 바다수선화 오일 및 라벤더 오일의 제조<Preparation Example 3> Preparation of daffodil oil and lavender oil
바다수선화 및 라벤더를 분쇄하여 바다수선화분말 및 라벤더분말을 준비하였다. 상기 바다수선화분말 및 라벤더분말을 1:1의 중량비율로 혼합하여 혼합분말을 준비하였다. 상기 혼합분말 10 g 및 헥산 90 g을 혼합하고, 35℃의 온도에서 3일 동안 교반하여 추출물을 제조하였다. 이를 여과하고 감압 농축한 후 원심분리하여 이물질을 제거하는 과정을 반복하였다. 최후 감압 증류를 반복함으로써 잔류용매인 헥산을 0.1 ppm 이하로 제거하여 이를 통해 바다수선화 오일 및 라벤더 오일을 제조하였다.Sea daffodil and lavender were pulverized to prepare daffodil powder and lavender powder. A mixed powder was prepared by mixing the daffodil powder and lavender powder in a weight ratio of 1:1. An extract was prepared by mixing 10 g of the mixed powder and 90 g of hexane and stirring at a temperature of 35° C. for 3 days. After filtering and concentrating under reduced pressure, the process of centrifuging to remove foreign substances was repeated. By repeating the last vacuum distillation, residual solvent, hexane, was removed to less than 0.1 ppm, and through this, daffodil oil and lavender oil were prepared.
<제조예 4> 소자 유래 엑소좀의 제조<Preparation Example 4> Preparation of element-derived exosomes
소자를 세척하여 초고압기에 넣고 30℃의 온도에서 300 MPa의 압력으로 3분 동안 전처리하였다. 전처리된 소자를 착즙기를 이용해 착즙하여 소자 착즙액을 제조하였다. 상기 소자 착즙액을 10,000xg에서 10분 동안 원심분리한 후, 상층액을 수득하였다. 상기 상층액을 -50℃의 온도에서 8시간 동안 동결건조하여 동결건조물을 제조하였다. 상기 동결건조물에 중량평균분자량 10,000-35,000인 폴리에틸렌글리콜 3.3 중량%와 중량평균분자량 400,000-500,000인 덱스트란을 1.7 중량%의 농도인 수용액을 사용하여 수성 2상계를 형성하였다. 상기 수성 2상계 내 엑소좀이 농축된 하층액을 수득하여 소자 유래 엑소좀을 제조하였다.After cleaning the device, it was placed in an ultra-high pressure machine and pretreated at a temperature of 30° C. and a pressure of 300 MPa for 3 minutes. The pretreated element was juiced using a juicer to prepare a element juice. After centrifuging the soybean juice at 10,000xg for 10 minutes, a supernatant was obtained. The supernatant was freeze-dried at -50 °C for 8 hours to prepare a lyophilisate. An aqueous two-phase system was formed using an aqueous solution containing 3.3% by weight of polyethylene glycol having a weight average molecular weight of 10,000 to 35,000 and 1.7% by weight of dextran having a weight average molecular weight of 400,000 to 500,000 to the lyophilisate. A lower layer in which exosomes were concentrated in the aqueous two-phase system was obtained to prepare device-derived exosomes.
<제조예 5> 미강 발효추출물의 제조<Preparation Example 5> Preparation of fermented rice bran extract
미강을 끓인 물로 3회 세척하고, 분쇄하여 미강분말을 준비하였다. 미강분말 10 g 및 물 300 g을 혼합하여 혼합물을 제조하고, 혼합물에 효모균으로 사카로미케스 케레비시아이(Saccharomyces cerevisiae)를 0.3 g 첨가한 후 35℃의 온도에서 24시간 동안 발효시켰다. 발효된 혼합물에 부틸렌글리콜 300 g을 혼합하고, 30℃의 온도에서 7일 동안 교반하여 추출물을 제조하였다. 상기 추출물을 여과 및 감압농축한 후 동결건조하여 미강 발효추출물을 제조하였다.Rice bran was washed three times with boiled water and ground to prepare rice bran powder. A mixture was prepared by mixing 10 g of rice bran powder and 300 g of water, and after adding 0.3 g of Saccharomyces cerevisiae as a yeast to the mixture, the mixture was fermented at 35° C. for 24 hours. An extract was prepared by mixing 300 g of butylene glycol with the fermented mixture and stirring at a temperature of 30° C. for 7 days. The extract was filtered and concentrated under reduced pressure, and then freeze-dried to prepare a fermented rice bran extract.
<제조예 6> 진두발 추출물, 대황 추출물, 우뭇가사리 추출물, 청각 추출물 및 톳 추출물의 제조<Preparation Example 6> Preparation of Jindubal extract, rhubarb extract, agar-agar extract, auditory extract and fusiformis extract
진두발, 대황, 우뭇가사리, 청각 및 톳을 세척하고 적절한 크기로 절단하여 준비하고, 세척된 진두발, 대황, 우뭇가사리, 청각 및 톳을 1:1:1:1:1의 중량비율로 혼합 및 분쇄하여 제1 혼합물을 제조하였다. 상기 제1 혼합물 10 중량부 및 물 90 중량부를 혼합하여 제2 혼합물을 제조하고, 상기 제2 혼합물을 95℃의 온도로 가열하고, 증발하는 증기를 냉각시켜 얻은 증류액이 다시 혼합물에 혼합되도록 하여 120분 동안 순환시켰다. 상기 순환이 완료된 제2 혼합물을 98-100℃의 온도로 가열하고, 180분 동안 증발하는 증기를 냉각시켜 1차 추출액을 얻었다. Prepare by washing Jindubal, Rhubarb, Agar-agar, Agar and Hijiki by cutting them into appropriate sizes, and mixing and grinding the washed Jindubal, Rhubarb, Agar-agar, Agaric and Hijiki at a weight ratio of 1:1:1:1:1 to prepare a first mixture. A second mixture is prepared by mixing 10 parts by weight of the first mixture and 90 parts by weight of water, the second mixture is heated to a temperature of 95 ° C, and the distillate obtained by cooling the evaporating vapor is mixed with the mixture again Circulated for 120 minutes. The second mixture after completion of the circulation was heated to a temperature of 98-100° C., and the evaporating vapor was cooled for 180 minutes to obtain a first extract.
상기 제2 혼합물의 고형분을 얻어 에탄올과 혼합한 후 50℃의 온도에서 4시간 동안 추출하여 2차 추출액을 얻었다.The solid content of the second mixture was obtained and mixed with ethanol, followed by extraction at a temperature of 50° C. for 4 hours to obtain a secondary extract.
상기 제1 추출액 및 제2 추출액을 감압농축한 후 동결건조 및 분쇄하여 진두발 추출물, 대황 추출물, 우뭇가사리 추출물, 청각 추출물 및 톳 추출물을 제조하였다.After concentrating the first extract and the second extract under reduced pressure, lyophilization and pulverization were performed to prepare Jindubal extract, rhubarb extract, agar-agar extract, auditory extract and fusiformis extract.
<실시예 1-3 및 비교예 1> 아토피 개선용 화장료 조성물의 제조<Example 1-3 and Comparative Example 1> Preparation of cosmetic composition for improving atopy
그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드, 상기 제조예 1에서 제조된 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출, 상기 제조예 2에서 제조된 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물, 상기 제조예 4에서 제조된 소자 유래 엑소좀, 상기 제조예 5에서 제조된 미강 발효추출물, 상기 제조예 6에서 제조된 진두발 추출물, 대황 추출물, 우뭇가사리 추출물, 청각 추출물 및 톳 추출물, 나이아신아마이드, 아르기닌, 아데노신, 디에칠아미노하이드록시벤조일헥실벤조에이트, 트라이에틸헥사노인, 스테아릴알코올, 이소퀘르시트린, 하이알루로닉애씨드, 소듐하이알루로네이트, 리모넨, 리날룰 및 브로콜리수를 혼합하고, 70℃의 온도에서 30분 동안 교반하여 제1 혼합조성물을 제조하였다.Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, fresh grass leaf extract prepared in Preparation Example 1, clover clover leaf extract and honeysuckle leaf extract, clover clover prepared in Preparation Example 2 Flower extract, Peony flower extract and Evening primrose extract, Soja-derived exosomes prepared in Preparation Example 4, Rice bran fermented extract prepared in Preparation Example 5, Jindubal extract prepared in Preparation Example 6, Rhubarb extract, Agar-agar extract, Auditory Extract and Hijiki Extract, Niacinamide, Arginine, Adenosine, Diethylaminohydroxybenzoylhexylbenzoate, Triethylhexanoin, Stearyl Alcohol, Isoquercitrin, Hyaluronic Acid, Sodium Hyaluronate, Limonene, A first mixed composition was prepared by mixing linalool and broccoli water and stirring at a temperature of 70° C. for 30 minutes.
상기 제조예 3에서 제조된 바다수선화 오일 및 라벤더 오일, 스쿠알란, 부틸렌글라이콜, 프로필렌글라이콜, 폴리글리세릴-6스테아레이트, 및 브로콜리수를 혼합하고, 40℃의 온도에서 60분 동안 교반하여 제2 혼합조성물을 제조하였다.Daffodil oil and lavender oil, squalane, butylene glycol, propylene glycol, polyglyceryl-6 stearate, and broccoli water prepared in Preparation Example 3 were mixed and stirred at a temperature of 40 ° C. for 60 minutes To prepare a second mixed composition.
상기 제1 혼합조성물 및 상기 제2 혼합조성물을 혼합하고, 50℃의 온도에서 20분 동안 교반하여 아토피 개선용 화장료 조성물을 제조하였다.The first mixed composition and the second mixed composition were mixed and stirred at a temperature of 50 ° C. for 20 minutes to prepare a cosmetic composition for improving atopy.
상기 아토피 개선용 화장료 조성물의 조성은 하기 표 1에 나타내었다.The composition of the cosmetic composition for improving atopy is shown in Table 1 below.
<실험예 1> 피부자극 실험<Experimental Example 1> Skin irritation test
상기 실시예 1-3 및 비교예 1에서 제조된 화장료 조성물의 피부자극 정도를 확인하기 위하여 피부 테스트를 실시하였다. 피부테스트를 위해 10-40대까지 각 연령대별로 5명씩 총 20명의 남녀를 상대로 위팔 부위에 화장료 조성물을 도포한 후 1시간 후에 피부 반응을 1차 육안 검사하고, 24시간 후에 다시 2차 육안 검사하여 그 결과를 하기의 표 2에 나타내었다.A skin test was conducted to confirm the degree of skin irritation of the cosmetic compositions prepared in Examples 1-3 and Comparative Example 1. For the skin test, a total of 20 men and women, 5 people from each age group from 10 to 40 years of age, applied the cosmetic composition to the upper arm area, and 1 hour later, the skin reaction was first visually inspected, and 24 hours later, a second visual inspection was performed. The results are shown in Table 2 below.
(○: 피부 변화 없음, △: 경미한 홍반이 나타남, ×:뚜렷한 홍반이 나타남)(○: No skin change, △: Slight erythema appeared, ×: Clear erythema appeared)
상기 표 2에 나타낸 바와 같이, 피부자극 실험 결과 이상이 없음을 확인하였다.As shown in Table 2, it was confirmed that there was no abnormality as a result of the skin irritation test.
<실험예 2> 아토피 개선 실험<Experimental Example 2> Atopy improvement experiment
상기 실시예 1-3 및 비교예 1에서 제조된 화장료 조성물의 아토피 피부염 증상완화 효과를 확인하기 위하여 실험을 수행하였다. 이를 위해 80명의 아토피성 피부 질환자를 20명씩 4그룹으로 나누어 1그룹에는 실시예 1의 화장료 조성물을, 2그룹에는 실시예 2의 화장료 조성물을, 3그룹에는 실시예 3의 화장료 조성물을, 4그룹에는 실시예 4의 화장료 조성물을 30일 동안 사용하도록 하여 가려움증 완화 및 아토피개선 효과를 분석하였으며, 그 결과를 하기 표 3에 나타내었다. 가려움증 완화는 5점 척도법으로 평가하였고, 아토피개선 효과는 0-100% 척도에 따른 평가를 수행하였다.Experiments were conducted to confirm the effect of alleviating the symptoms of atopic dermatitis of the cosmetic compositions prepared in Examples 1-3 and Comparative Example 1. To this end, 80 atopic skin disease patients were divided into 4 groups of 20 each, 1 group received the cosmetic composition of Example 1, 2 groups received the cosmetic composition of Example 2, 3 groups received the cosmetic composition of Example 3, and 4 groups received the cosmetic composition of Example 2. In, the cosmetic composition of Example 4 was used for 30 days to analyze the itching relief and atopy improvement effects, and the results are shown in Table 3 below. Itching relief was evaluated on a 5-point scale, and the atopy improvement effect was evaluated on a 0-100% scale.
가려움증완화에 대해서 1점은 매우나쁘다, 2점은 나쁘다, 3점은 보통이다, 4점은 좋다, 5점은 매우좋다이고, 아토피개선효과에 대해서 0%는 치유효과없음, 25%는 약간개선, 50%는 적당히개선, 75%는 상당한개선, 100%는 완전치유이다.For itching relief, 1 point is very bad, 2 points are bad, 3 points are average, 4 points are good, 5 points are very good, and 0% is no healing effect and 25% is slightly improved for the atopy improvement effect. , 50% is moderate improvement, 75% is significant improvement, and 100% is complete healing.
상기 표 3에 나타낸 바와 같이, 본 발명에 따른 아토피 개선용 화장료 조성물은 아토피 피부염에 대해 가려움증 완화 및 개선 효과가 있음을 확인하였다.As shown in Table 3, it was confirmed that the cosmetic composition for improving atopy according to the present invention has an effect of alleviating and improving itching for atopic dermatitis.
Claims (5)
상기 아토피 개선용 화장료 조성물은,
그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 2-4 중량부, 신선초잎 추출물 0.5-1.5 중량부, 싸리나무잎 추출물 0.5-1.5 중량부, 인동덩굴잎 추출물 0.5-1.5 중량부, 싸리나무꽃 추출물 0.5-1.5 중량부, 작약꽃 추출물 0.5-1.5 중량부, 달맞이꽃 추출물 0.5-1.5 중량부, 바다수선화 오일 0.5-1.5 중량부, 라벤더 오일 0.5-1.5 중량부, 소자 유래 엑소좀 0.5-1.5 중량부, 나이아신아마이드 1-3 중량부, 아르기닌 0.5-1.5 중량부, 아데노신 0.5-1.5 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.5-1.5 중량부, 트라이에틸헥사노인 0.5-1.5 중량부, 스쿠알란 4-6 중량부, 부틸렌글라이콜 3-5 중량부, 프로필렌글라이콜 0.08-0.12 중량부, 폴리글리세릴-6스테아레이트 0.08-0.12 중량부, 스테아릴알코올 0.08-0.12 중량부, 이소퀘르시트린 0.08-0.12 중량부, 하이알루로닉애씨드 1-3 중량부, 소듐하이알루로네이트 0.08-0.12 중량부, 리모넨 0.4-0.6 중량부, 리날룰 0.5-1.5 중량부 및 브로콜리수 68-70 중량부를 포함하는 것을 특징으로 하는 아토피 개선용 화장료 조성물.According to claim 1,
The cosmetic composition for improving atopy,
2-4 parts by weight of Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, 0.5-1.5 parts by weight of fresh grass leaf extract, 0.5-1.5 parts by weight of clover leaf extract, 0.5-1.5 parts by weight of honeysuckle leaf extract 1.5 parts by weight, clover flower extract 0.5-1.5 parts by weight, peony flower extract 0.5-1.5 parts by weight, evening primrose extract 0.5-1.5 parts by weight, sea daffodil oil 0.5-1.5 parts by weight, lavender oil 0.5-1.5 parts by weight, Soja Exosome 0.5-1.5 parts by weight, niacinamide 1-3 parts by weight, arginine 0.5-1.5 parts by weight, adenosine 0.5-1.5 parts by weight, diethylaminohydroxybenzoylhexylbenzoate 0.5-1.5 parts by weight, triethylhexanoin 0.5 parts by weight -1.5 parts by weight, squalane 4-6 parts by weight, butylene glycol 3-5 parts by weight, propylene glycol 0.08-0.12 parts by weight, polyglyceryl-6 stearate 0.08-0.12 parts by weight, stearyl alcohol 0.08- 0.12 parts by weight, isoquercitrin 0.08-0.12 parts by weight, hyaluronic acid 1-3 parts by weight, sodium hyaluronate 0.08-0.12 parts by weight, limonene 0.4-0.6 parts by weight, linalool 0.5-1.5 parts by weight and A cosmetic composition for improving atopy, comprising 68-70 parts by weight of broccoli water.
싸리나무꽃, 작약꽃 및 달맞이꽃을 세척하고 동결건조한 후 분쇄하여 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 제조하는 단계; 제조된 싸리나무꽃분말, 작약꽃분말 및 달맞이꽃분말을 1:1:1의 중량비율로 혼합한 혼합분말 20 g을 물 200 ml와 혼합하고, 교반하면서 80℃의 온도에서 8시간 동안 1차 열수추출을 수행하는 단계; 1차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 1차 혼합추출물을 제조하는 단계; 1차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 교반하면서 120℃의 온도에서 12시간 동안 2차 열수추출을 수행하는 단계; 2차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 2차 혼합추출물을 제조하는 단계; 2차 열수추출 후 여과지로 여과한 다음 남은 고형물을 다시 물과 혼합하되, 고형물 및 물의 혼합비율이 0.1 g/ml가 되도록 혼합하고, 여기에 [BMIm][TFSI](1-Butyl-3-methylimidazoliumbis trifluoromethylsulfonyl)imide)를 1-2 g 첨가한 후 교반하면서 100℃의 온도에서 8시간 동안 3차 열수추출을 수행하는 단계; 3차 열수추출 후, 여과지로 여과한 다음 그 여액을 동결건조하여 3차 혼합추출물을 제조하는 단계; 및 상기 1차 혼합추출물, 2차 혼합추출물 및 3차 혼합추출물을 혼합하는 단계;를 포함하는 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물을 제조하는 단계;
바다수선화 및 라벤더를 분쇄하여 바다수선화분말 및 라벤더분말을 준비하는 단계; 상기 바다수선화분말 및 라벤더분말을 1:1의 중량비율로 혼합한 혼합분말 및 헥산을 혼합하고, 33-37℃의 온도에서 2-4일 동안 교반하여 추출물을 제조하는 단계; 및 상기 추출물을 여과하고 감압농축한 후 원심분리하여 이물질을 제거한 후, 감압증류하는 단계;를 포함하는 바다수선화 오일 및 라벤더 오일을 제조하는 단계;
소자를 세척하여 28-32℃의 온도에서 290-310 MPa의 압력으로 1-5분 동안 전처리하는 단계; 전처리된 소자를 착즙하여 소자 착즙액을 제조하는 단계; 상기 소자 착즙액을 원심분리하여 엑소좀을 포함하는 상층액을 수득하는 단계; 상기 엑소좀을 포함하는 상층액을 동결건조하여 동결건조물을 제조하는 단계; 상기 동결건조물에 폴리에틸렌글리콜/덱스트란을 사용하여 수성 2상계를 형성하는 단계; 및 상기 수성 2상계 내 엑소좀이 농축된 하층액을 수득하는 단계;를 포함하는 소자 유래 엑소좀을 제조하는 단계;
그라모스툴라 스파툴라타 메카노톡신 4(Grammostula spatulata mechanotoxin 4, GsMTx4) 펩타이드 1-5 중량부, 상기에서 제조된 신선초잎 추출물, 싸리나무잎 추출물 및 인동덩굴잎 추출물 1-5 중량부, 상기에서 제조된 싸리나무꽃 추출물, 작약꽃 추출물 및 달맞이꽃 추출물 1-5 중량부, 상기에서 제조된 소자 유래 엑소좀 0.3-3 중량부, 나이아신아마이드 0.5-4 중량부, 아르기닌 0.3-3 중량부, 아데노신 0.3-3 중량부, 디에칠아미노하이드록시벤조일헥실벤조에이트 0.3-3 중량부, 트라이에틸헥사노인 0.3-3 중량부, 스테아릴알코올 0.05-0.2 중량부, 이소퀘르시트린 0.05-0.2 중량부, 하이알루로닉애씨드 0.5-4 중량부, 소듐하이알루로네이트 0.05-0.2 중량부, 리모넨 0.3-0.7 중량부, 리날룰 0.3-3 중량부 및 브로콜리수 47-51 중량부를 혼합하고, 68-72℃의 온도에서 28-32분 동안 교반하여 제1 혼합조성물을 제조하는 단계;
상기에서 제조된 바다수선화 오일 및 라벤더 오일 0.5-4 중량부, 스쿠알란 3-7 중량부, 부틸렌글라이콜 2-6 중량부, 프로필렌글라이콜 0.05-0.2 중량부, 폴리글리세릴-6스테아레이트 0.05-0.2 중량부 및 브로콜리수 18-22 중량부를 혼합하고, 38-42℃의 온도에서 58-62분 동안 교반하여 제2 혼합조성물을 제조하는 단계; 및
상기 제1 혼합조성물 및 상기 제2 혼합조성물을 혼합하고, 48-52℃의 온도에서 18-22분 동안 교반하는 단계;를 포함하는 아토피 개선용 화장료 조성물의 제조방법.Preparing fresh herb leaf powder, clover clover leaf powder, and honeysuckle leaf powder by washing, freeze-drying, and pulverizing fresh herb leaves, clover clover leaf and honeysuckle leaf; Prepared fresh herb leaf powder, clover leaf powder and honeysuckle leaf powder were mixed in a weight ratio of 1: 1: 1, and a mixed solvent in which ethanol and hexane were mixed in a volume ratio of 1: 1 and a weight ratio of 1: 9 preparing an extract by mixing and extracting at a temperature of 28-32 ° C for 22-26 hours; and filtering the extract with a filter paper, concentrating the filtered filtrate under reduced pressure and freeze-drying the filtrate at minus 50 ° C.
Preparing clover flower powder, peony flower powder, and evening primrose powder by washing, freeze-drying, and pulverizing clover flower, peony flower, and evening primrose; 20 g of the prepared mixed powder of clover flower powder, peony flower powder, and evening primrose powder mixed in a weight ratio of 1:1:1 was mixed with 200 ml of water, followed by primary hot water at 80°C for 8 hours while stirring. performing an extraction; After the first hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a first mixed extract; After the first hot water extraction, the remaining solids were filtered with filter paper, and the remaining solids were mixed with water so that the mixing ratio of the solids and water was 0.1 g/ml, and the second hot water extraction was performed at a temperature of 120 ° C for 12 hours while stirring. doing; After secondary hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a secondary mixed extract; After the second hot water extraction, filter with filter paper, and mix the remaining solids with water again so that the mixing ratio of solids and water is 0.1 g/ml, and [BMIm][TFSI](1-Butyl-3-methylimidazolium After adding 1-2 g of trifluoromethylsulfonyl)imide), performing a third hot water extraction at a temperature of 100 ° C. for 8 hours while stirring; After tertiary hot water extraction, filtering with filter paper and then freeze-drying the filtrate to prepare a tertiary mixed extract; And mixing the first mixed extract, the second mixed extract and the tertiary mixed extract; preparing a bush clover flower extract, a peony flower extract and an evening primrose extract containing;
Preparing sea daffodil powder and lavender powder by crushing sea daffodil and lavender; preparing an extract by mixing a mixture of daffodil powder and lavender powder in a weight ratio of 1:1 with hexane and stirring at a temperature of 33-37 ° C. for 2-4 days; Preparing sea daffodil oil and lavender oil comprising; filtering and concentrating the extract under reduced pressure, centrifuging to remove foreign substances, and distilling under reduced pressure;
washing the device and pre-treating it at a temperature of 28-32° C. and a pressure of 290-310 MPa for 1-5 minutes; Preparing a device juice by extracting the pretreated device; Obtaining a supernatant containing exosomes by centrifuging the juice from the cow; preparing a lyophilisate by freeze-drying the supernatant containing the exosomes; forming an aqueous two-phase system using polyethylene glycol/dextran in the lyophilisate; and obtaining an exosome-enriched lower layer in the aqueous two-phase system; preparing a device-derived exosome comprising;
1-5 parts by weight of Grammostula spatulata mechanotoxin 4 (GsMTx4) peptide, 1-5 parts by weight of the above-prepared cinnamon leaf extract, clover clover leaf extract and honeysuckle leaf extract, 1-5 parts by weight of Hsagi flower extract, peony flower extract and evening primrose extract prepared above, 0.3-3 parts by weight of the device-derived exosome prepared above, 0.5-4 parts by weight of niacinamide, 0.3-3 parts by weight of arginine, 0.3 parts by weight of adenosine -3 parts by weight, diethylaminohydroxybenzoylhexylbenzoate 0.3-3 parts by weight, triethylhexanoin 0.3-3 parts by weight, stearyl alcohol 0.05-0.2 parts by weight, isoquercitrin 0.05-0.2 parts by weight, hyaluronic acid 0.5-4 parts by weight of rhonic acid, 0.05-0.2 parts by weight of sodium hyaluronate, 0.3-0.7 parts by weight of limonene, 0.3-3 parts by weight of linalool and 47-51 parts by weight of broccoli water were mixed, and Stirring for 28-32 minutes at a temperature to prepare a first mixed composition;
0.5-4 parts by weight of daffodil oil and lavender oil prepared above, 3-7 parts by weight of squalane, 2-6 parts by weight of butylene glycol, 0.05-0.2 parts by weight of propylene glycol, polyglyceryl-6 stearate Preparing a second mixed composition by mixing 0.05-0.2 parts by weight and 18-22 parts by weight of broccoli water and stirring at a temperature of 38-42 ° C. for 58-62 minutes; and
Mixing the first mixed composition and the second mixed composition, and stirring at a temperature of 48-52 ° C. for 18-22 minutes; Method for producing a cosmetic composition for improving atopy comprising the.
상기 제1 혼합조성물은 미강 발효추출물을 0.3-3 중량부 포함하는 것을 특징으로 하는 아토피 개선용 화장료 조성물의 제조방법.According to claim 4,
The first mixed composition is a method for producing a cosmetic composition for improving atopy, characterized in that it comprises 0.3-3 parts by weight of rice bran fermentation extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230024252A KR102539462B1 (en) | 2023-01-25 | 2023-02-23 | Manufacturing method of atopic skin improving cosmetic composition containing Angelica keiskei |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20230009236 | 2023-01-25 | ||
KR1020230009236 | 2023-01-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020230024252A Division KR102539462B1 (en) | 2023-01-25 | 2023-02-23 | Manufacturing method of atopic skin improving cosmetic composition containing Angelica keiskei |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102539450B1 true KR102539450B1 (en) | 2023-06-02 |
Family
ID=86755423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020230023688A KR102539450B1 (en) | 2023-01-25 | 2023-02-22 | Method for manufacturing atopic dermatitis-improving cosmetic composition containing tarantula component |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102539450B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070042310A (en) * | 2005-10-18 | 2007-04-23 | 재단법인서울대학교산학협력재단 | Recombinant yeast expression plasmid having gsmtx4 gene and method for mass-producing gsmtx4, grammostola spatulata toxin peptide using the same |
KR20070095588A (en) * | 2006-03-22 | 2007-10-01 | 유니크인터네셔널 주식회사 | Nature room composite and the manufacture method for atopiseong skin disease treatment |
KR100761792B1 (en) * | 2006-01-06 | 2007-10-04 | 재단법인서울대학교산학협력재단 | 4 ANALGESIC COMPOSITION CONTAINING GsMTx4 PEPTIDE AND ITS DERIVATIVES AS COMPONENT |
KR20140017761A (en) * | 2012-07-31 | 2014-02-12 | 주식회사 인섹트 바이오텍 | A composition containing arazyme for the prevention and treatment of atopic dermatitis |
KR20220001541A (en) * | 2020-06-29 | 2022-01-06 | 군산대학교산학협력단 | Composition for preventing, improving, or treating inflammation comprising peptides derived From Haliotis Discus as effective component |
-
2023
- 2023-02-22 KR KR1020230023688A patent/KR102539450B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070042310A (en) * | 2005-10-18 | 2007-04-23 | 재단법인서울대학교산학협력재단 | Recombinant yeast expression plasmid having gsmtx4 gene and method for mass-producing gsmtx4, grammostola spatulata toxin peptide using the same |
KR100761792B1 (en) * | 2006-01-06 | 2007-10-04 | 재단법인서울대학교산학협력재단 | 4 ANALGESIC COMPOSITION CONTAINING GsMTx4 PEPTIDE AND ITS DERIVATIVES AS COMPONENT |
KR20070095588A (en) * | 2006-03-22 | 2007-10-01 | 유니크인터네셔널 주식회사 | Nature room composite and the manufacture method for atopiseong skin disease treatment |
KR20140017761A (en) * | 2012-07-31 | 2014-02-12 | 주식회사 인섹트 바이오텍 | A composition containing arazyme for the prevention and treatment of atopic dermatitis |
KR20220001541A (en) * | 2020-06-29 | 2022-01-06 | 군산대학교산학협력단 | Composition for preventing, improving, or treating inflammation comprising peptides derived From Haliotis Discus as effective component |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumar et al. | Recent trends in potential traditional Indian herbs Emblica officinalis and its medicinal importance | |
KR101868050B1 (en) | Fermentation method using medicinal flower and skin external composition containing fermented extract by the method | |
KR101805004B1 (en) | Fermentation method using medicinal leaf and skin external composition containing fermented extract by the method | |
KR101233857B1 (en) | Cosmetic composition with natural orientalplant extract | |
KR101445776B1 (en) | Composition for mask pack comprising culture extract of Edelweiss or Opuntia humifusa and manufacturing the same and mask pack using the same | |
KR101315265B1 (en) | Cosmetic composition for improving skin senescence | |
KR20080094459A (en) | Cosmetic composition having antioxidation activity | |
KR20120038585A (en) | Oriental medicine extract for prevention of alopecia and hair article composition | |
KR101412500B1 (en) | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof | |
KR102113645B1 (en) | A cosmetic composition for preventing hair loss and promoting hair growth containing spicule powder and natural extract | |
KR102004366B1 (en) | A cosmetic composition comprising centipeda minima extract | |
KR20110110995A (en) | Cosmetic composition and mask pack comprising the same | |
KR102551199B1 (en) | Manufacturing method of high-concentration vitamin C cosmetic composition | |
KR100878080B1 (en) | A composite of nutrition pack for skin beauty and making method thereof | |
KR101628939B1 (en) | Cosmetic composition for improving atopic dermatitis and dry skin containing the botanical extracts prepared by bioconversion | |
KR20150029672A (en) | My skin health and beauty using the functional bio-ceramic and 107 kinds of native grasses | |
KR101944764B1 (en) | High moisturized cosmetical composition using natural plant extract and lipstick comprising the same | |
KR100981344B1 (en) | The cosmetic composition for preventing the skin aging | |
KR20160100745A (en) | Functional Cosmetic Compositions of Bio-Conversion using Solid State Fermentation and Functional Cosmetics Produced Thereby | |
KR102330277B1 (en) | Cosmetics composition comprising centella asiatica extracts | |
KR102539450B1 (en) | Method for manufacturing atopic dermatitis-improving cosmetic composition containing tarantula component | |
KR102539462B1 (en) | Manufacturing method of atopic skin improving cosmetic composition containing Angelica keiskei | |
KR20180089696A (en) | Removing Method for Residual Agricultural Chemicals of Natural Plant Extracts | |
KR102496150B1 (en) | Skin-Brightening Cosmetic Compositions Comprising HWANGCHIL Extract and ECKLONIA CAVA Extract and Preparation Methods Thereof | |
KR20140111364A (en) | My skin health and beauty using the functional bio-ceramic and 107 kinds of native grasses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |